References with PepMix™ Peptide Pools - Infectious Diseases



  • A vaccine targeting antigen-presenting cells through CD40 induces protective immunity against Nipah disease
    Pastor et al., Cell Reports Medicine (2024) - PMID: 38471503
    Products used: PepMix Nipah Virus (Nucleoprotein N)Nipah virus (Glycoprotein G), Nipah Virus (Fusion Glycoprotein F0) and ECD
  • Rejection resistant CD30.CAR-modified Epstein-Barr virus specific T cells as an offthe-shelf platform for CD30+ lymphoma
    Quach et al., Molecular Therapy: Oncology (2024) 
    Products used: PepMix EBV (EBNA1)EBV (BZLF1)EBV (LMP1)EBV (LMP2)
  • Cytomegalovirus UL44 protein induces a potent T-cell immune response in mice
    Mancebo et al., Antiviral Research (2024) 
    Products used: Custom PepMix CMV UL44, PepMix Human CMV (pp65)
  • SARS-CoV-2-specific immune responses converge in kidney disease patients and controls with hybrid immunity
    Aguilar-Bretones et al., Vaccines (2024) 
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • An IL-10 homologue encoded by human cytomegalovirus is linked with the viral “footprint” in clinical samples
    Veld et al., Cytokine (2024) 
    Product used: PepMix Human CMV (IE-1)
  • Imbalance of SARS-CoV-2-specific CCR6+ and CXCR3+ CD4+ T cells and IFN-γ + CD8+ T cells in patients with Long-COVID
    Martínez-Fleta et al., Clinical Immunology (2024) 
    Products used: PepMix SARS-CoV-2 (NCAP), PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 SUB2)
  • Optimizing SARS-CoV-2 vaccine responses in kidney transplant recipients: an urgent need
    Cheng et al., Microbiology Spectrum (2024) - PMID: 38747636
    Products used: PepMix SARS-CoV-2 (Spike B.1.617.2 / Delta)SARS-CoV-2 (Spike B.1.1.529 / BA.2 / Omicron)
  • Modulation of innate immune response to mRNA vaccination after SARS-CoV-2 infection or sequential vaccination in humans
    Hellgren et al., JCI Insight (2024)
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • Intranasal vaccination with an NDVvectored SARS-CoV-2 vaccine protects against Delta and Omicron challenges
    Warner et al., Vaccines (2024) - PMID: 38782986
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • Kinetics of pro- and anti-inflammatory spike-specific T-cell responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: A prospective longitudinal study in Japan
    Kakugawa et al., Research Square (2024)
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • Nasal vaccination of triple-RBD scaffold protein with flagellin elicits long-term protection against SARS-CoV-2 variants including JN.1
    Li et al., Signal Transduction and Targeted Therapy (2024) - PMID: 38678055
    Product used: PepMix SARS-CoV-2 (S-RBD)
  • Gene replacement therapy in Bietti crystalline corneoretinal dystrophy: an open-label, single-arm, exploratory trial
    Wang et al., Signal Transductions and Targeted Therapy (2024) - PMID: 38653979
    Product used: PepMix AAV8 (Capsid protein)
  • A bivalent COVID-19 mRNA vaccine, PTX-COVID19-M1.2, elicited broad immune responses and protected animals from SARS-CoV-2 Omicron subvariants infection
    Wang et al., Research Square (2024) 
    Products used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron)SARS-CoV-2 (Spike XBB.1.5)
  • Immunogenicity and Protective Efficacy of Psoralen-Inactivated SARS-CoV-2 Vaccine in Nonhuman Primates
    Sanders et al., Vaccines (2024) 
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • Antigen clustering effect on immunogenicity in prefusion-stabilized spike-based COVID-19 vaccines
    Matthews et al., Research Square (2024) 
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1)
  • Co-targeting EBV lytic as well as latent cycle antigens increases T-cell potency against lymphoma
    Sharma et al., Blood Advances (2024) 
    Products used: PepMix EBV (BZLF1)EBV (BRLF1)EBV (BMRF1)
  • Third-party virus specific T cells for the treatment of double stranded DNA viral reactivation and PTLD after solid organ transplant
    Khoury et al., American Journal of Transplantation
    Products used: PepMix EBV (BZLF1), EBV (LMP2)EBV (EBNA1)
  • Preclinical evaluation of two phylogenetically distant arenavirus vectors for the development of novel immunotherapeutic combination strategies for cancer treatment
    Raguz et al., Journal for Immunotherapy of Cancer (2024) - PMID: 38631709
    Products used: PepMix HPV 16 (E6)HPV 16 (E7)
  • Lack of functional TCR-epitope interaction is associated with herpes zoster through reduced downstream T cell activation
    Boeren et al., Cell Reports (2024) - PMID: 38588339
    Product used: PepMix Influenza A (Neuroamidase /California (H1N1)VZV (gE)VZV (IE62)_2 subpoolsVZV (IE63)
  • COVID-19 vaccination induces distinct T-cell responses in pediatric solid organ transplant recipients and immunocompetent children
    Roznik et al., Vaccines (2024) 
    Products used: PepMix SARS-CoV-2 (Spike Glycoprotein)SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron)
  • Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity
    Wolz et al., Vaccines (2024) 
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • The Micro-Immunotherapy Medicine 2LPAPI® Displays Immune-Modulatory Effects in a Model of Human Papillomavirus Type-16 L1-Protein Capsid-Treated Human Peripheral Blood Mononuclear Cells and Antiproliferative Effects in a Model of Cervical Cancer Cells
    Jacques et al., Cancers (2024) 
    Product used: PepMix HPV16 (L1)
  • From Vaccination to Infection: Mechanistic Studies of Immune Responses to SARS-COV-2
    Lenart, Dissertation (2024) 
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • Immunogenicity and efficacy of VLA2001 vaccine against SARS-CoV-2 infection in male cynomolgus macaques
    Galhaut et al., Communications Medicine (2024) - PMID: 38570605
    Products used: PepMix SARS-CoV-2 (S-RBD),  SARS-CoV-2 (NCAP)
  • Evaluation of T Cell Response to SARS-CoV-2 in Kidney Transplant Recipients Receiving Monoclonal Antibody Prophylaxis and the Utility of a Bivalent mRNA Vaccine Booster Dose
    Bertrand et al., Microorganisms (2024) 
    Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 (NCAP)SARS-CoV-2 (NS7A)SARS-CoV-2 (VEMP)SARS-CoV-2 (VME1)SARS-CoV-2 (Nsp3)CEFX Ultra SuperStim Pool
  • Carrier-free mRNA vaccine induces robust immunity against SARS-CoV-2 in mice and non-human primates without systemic reactogenicity
    Abbasi et al., Molecular Therapy (2024) 
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination
    Verstegen et al., Multiple Sclerosis (2024) - PMID: 38548324
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 SUB2)
  • Children treated against lymphoid malignancies display diminished IFN-gamma producing T cells after polyclonal and Varicella zoster virus peptide activation
    Tiselius et al., Research Square (2024) 
    Product used: PepMix VZV (gE) and VZV (IE63)
  • LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study
    Musher et al., The Lancet Oncology (2024) - PMID: 38547893
    Product used: PepMix Human Adenovirus 26 (Hexon Protein) and Human Adenovirus 26 (Penton Protein)
  • Comparable CD8+ T‐cell responses to SARS‐CoV‐2 vaccination in single‐cell transcriptomics of recently allogeneic transplanted patients and healthy individuals
    Tranter et al., Journal of Medical Virology (2024) 
    Product used: CEFX Ultra SuperStim Pool, PepMix SARS-CoV-2 (NCAP), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 AP3A (ORF3a)SARS-CoV-2 NS7ASARS-CoV-2 NS8, Pan‐SARS-CoV-2 Select, and custom PepMix
  • Generation of CRISPR-Cas9-edited Tacrolimus-resistant SARS-CoV-2-specific T-cells for adoptive cell therapy in transplant patients
    Peter, Dissertation (2024)
    Products used: PepMix CMVA (pp65), SARS-CoV-2 peptide pools (NCAP, Spike S1, Spike S2, VEMP, VME1, AP3a, NS6, NS7a, NS7b, NS8, ORF9b, ORF10, Y14)
  • LVS ΔcapB-vectored multiantigenic melioidosis vaccines protect against lethal respiratory Burkholderia pseudomallei challenge in highly sensitive BALB/c mice
    Tullius et al., Vaccines (2024) 
    Product used: PepMix BKV (small T antigen)
  • Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine
    Harris et al., Vaccines (2024) 
  • Development and Characterization of a Novel DC-Targeting Universal Influenza Vaccine
    Olukitibi et al., Dissertation (2024) 
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1)
  •  A vaccine targeting antigen-presenting cells through CD40 induces protective immunity against Nipah disease 
    Pastor et al., Cell Reports Medicine (2024) - PMID: 38471503
    Products used: PepMix Nipah Virus (Nucleoprotein N)Nipah virus (Glycoprotein G),  Nipah Virus (Fusion Glycoprotein F0), custom PepMix Nipah ECD
  • Single MVA-SARS-2-ST/N Vaccination Rapidly Protects K18-hACE2 Mice against a Lethal SARS-CoV-2 Challenge Infection
    Clever et al., Viruses (2024) 
    Product used: PepMix SARS-CoV-2 (NCAP)SARS-CoV-2 Antigen Peptide NCAP (LALLLLDRL)Antigen Peptide IFN-gR H-2 Kb (TSYKFESV)
  • NFκB and NLRP3/NLRC4 inflammasomes regulate differentiation, activation and functional properties of monocytes in response to distinct SARS-CoV-2 proteins
    Tsukalov et al., Nature Communications (2024) - PMID: 38453949
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1)SARS-CoV-2 (NCAP)
  • Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study
    Reiter et al., Scientific Reports (2024) - PMID: 38438427
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • Ad26.M.Env ZIKV vaccine protects pregnant rhesus macaques and fetuses against Zika virus infection
    Martinot et al., Research Square (2024) 
    Product used: PepMix ZIKV (E) UltraZIKV (M) Ultra
  • Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial.
    Pant et al., Nature Medicine (2024) - PMID: 38195752
    Product used: PepMix Pan-CMV SelectCMVA (pp65)SARS-CoV-2 (S-RBD)
  • Cognate Antigen Engagement induces HIV-1 Expression in CD4+ T cells from people in long-term Art
    Moskovljevic et al., BioRxiv (2024) 
    Product used: PepMix™ HIV-1 (GAG) Ultra
  • Bivalent mRNA COVID vaccines elicit predominantly cross-reactive CD4+ T cell clonotypes
    Sop et al., Cell Reports Medicine (2024) - PMID: 38423018
    Products used: PepMix SARS-CoV-2 (Spike Glycoprotein)SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron)
  • Immune responses to SARS-CoV-2 mRNA vaccination in people with idiopathic CD4 lymphopenia
    Rocco et al., Translational and Clinical Immunology (2024) - PMID: 38344971
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth
    Wang et al., Vaccines (2024) - PMID: 38378950
    Product used: custom PepStar, PepMix™ CMVA (UL55)
  • Applying valency-based immuno-selection to generate broadly cross-reactive antibodies against influenza hemagglutinins
    Hinke et al., Nature Communications (2024) - PMID: 38346952
    Products used: PepMix™ Influenza A (HA/Puerto Rico/8/1934 H1N1), PepMix™ Influenza A (HA /California (H1N1))
  • Integrating Machine Learning-Enhanced Immunopeptidomics and SARS-CoV-2 PopulationScale Analyses Unveils Novel Antigenic Features for Next-Generation COVID-19 Vaccines
    Caron et al., Research Square (2024) 
    Product used: PepMix™ HIV-1 (POL) Ultra
  • Vaccines targeting ESR1 activating mutations elicit anti-tumor immune responses and suppress estrogen signaling in therapy resistant ER+ breast cancer
    Dailey et al., Human Vaccines & Immunotherapeutics (2024) - PMID: 38330990
    Products used: Custom PepMix (ESR1), PepMix™ HIV-1 (GAG) Ultra
  • A Gamma-adapted subunit vaccine induces broadly neutralizing antibodies against SARS-CoV-2 variants and protects mice from infection
    Coria et al., Nature Communications (2024) - PMID: 38307851
    Products used: PepMix™ SARS-CoV-2 (S-RBD), PepMix™ SARS-CoV-2 (S-RBD P.1 / Gamma)
  • Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer 
    Debie et al., Clinical Cancer Research (2024) - PMID: 36341493
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 SUB2)
  • Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
    Pant et al., Nature Medicine (2024) - PMID: 38195752
    Products used: PepMix™ SARS-CoV-2 (S-RBD),CEFSX Ultra SuperStim Pool, CEFT Pool, PepMix™ Pan-CMV Select, PepMix CMVA pp65, PepMix™ Pan-EBV Select, CEF Pool (standard) 
  • MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans
    Mayer et al., Vaccines (2024) - PMID: 38278816
    Product used: CEF Pool (extended), PepMix™SARS-CoV-2 (Spike Glycoprotein) 
  • Low pre-existing endemic human coronavirus (HCoV-NL63)-specific T cell frequencies are associated with impaired SARS-CoV-2-specific T cell responses in people living with HIV
    Ng'uni et al., Frontiers in Immunology (2024)
    Products used: PepMix™ SARS-CoV-2 (Spike B.1.617.2 / Delta), PepMix™ HCoV-NL63 (Spike Glycoprotein), PepMix™ SARS-CoV-2 (Spike B.1.351 / Beta)
  • T Cell Responses against Orthopoxviruses in HIV-Positive Patients
    Stefanie et al., Vaccines (2024)
    Product used: PepMix™ Pan-Poxviridae Select 
  • Caveats of chimpanzee ChAdOx1 adenovirus-vectored vaccines to boost anti-SARS-CoV-2 protective immunity in mice
    Cervantes-Torres et al., Applied Microbiology and Biotechnology (2024) - PMID: 38280035
    Product used: PepMix™ SARS-CoV-2 (S-RBD B.1.617.2 / Delta) 
  • Comparison of Omicron Breakthrough Infection Versus Monovalent SARS-CoV-2 Intramuscular Booster Reveals Differences in Mucosal and Systemic Humoral Immunity
    Nantel et al., Mucosal Immunology (2024)
    Products used: PepMix™SARS-CoV-2 (Spike P.1 / Gamma), PepMix™ SARS-CoV-2 (Spike B.1.351 / Beta), PepMix™ SARS-CoV-2 (Spike B.1.617.2 / Delta), PepMix™ SARS-CoV-2 (Spike B.1.1.7 / Alpha), PepMix™ SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron) 
  • Expanded specific T cells to hypomutated regions of the SARS-CoV-2 using mRNA electroporated antigen presenting cells.
    Ogando-Rivas et al., Methods and Clinical Development (2024)
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), PepMix™ SARS-CoV-2 (VME1), PepMix™ SARS-CoV-2 (VEMP), PepMix™SARS-CoV-2 (NCAP) 
  • Enhanced detection of antigen-specific T cells by a multiplexed AIM assay
    Lemieux et al., Cell Rep Methods (2024) - PMID: 38228152
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), PepMix™ HIV-1 (GAG) Ultra, PepMix™ HIV-1 (POL) Ultra, PepMix™ HIV-1 (ENV) Ultra, PepMix™ HIV-1 (NEF) Ultra, PepMix™ CMVA (pp65) 
  • Three immunizations with Novavax’s protein vaccines increase antibody breadth and provide durable protection from SARSCoV-2
    Lenart et al., Vaccines (2024) - PMID: 38245545
    Products used: PepMix™SARS-CoV-2 (Spike Glycoprotein) 
  • Identification of a spike-specific CD8+ T cell epitope following vaccination against the Middle East respiratory syndrome coronavirus in humans
    Harrer et al., Journal of Infectious Diseases (2024) - PMID: 38195212
    Products used: PepMix™ MERS-CoV (Spike Glycoprotein), CEF Pool (extended) 
  • Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity
    Muñoz-Alía et al., mBio (2024) - PMID: 38193729
    Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) 
  • CD3-downregulation identifies T-helper-cells with superior functionality and distinct metabolism in SARS-CoV2-vaccination- and recall-antigen-specific immunity
    Sattler et al., JCI Insight (2024)
    Products used: PepMix™ SARS-CoV-2 (Spike B.1.1.7 / Alpha)SARS-CoV-2 Antigen Peptide Spike Fusion (SFIEDLLFNKVTLAD) 
  • Humoral and cellular immune responses after COVID-19 vaccination of lung transplant recipients and patients on the waiting list: a 6-month follow-up
    Hoek et al., Frontiers in Immunology (2024)
    Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) 
  • Protective MVA-ST Vaccination Robustly Activates T Cells and Antibodies in an Aged-Hamster Model for COVID-19
    Clever et al., Vaccines (2024)
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein) 
  • Optimising a linear ‘Doggybone’ DNA vaccine for influenza virus through the incorporation of DNA targeting sequences and neuraminidase antigen
    Cunliffe et al., Discovery Immunology (2024)'
    Product used: PepMix Influenza A (Neuroamidase /California (H1N1) 
  • A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validation
    Binayke et al., NPJ Vaccines (2024) - PMID: 38167915
    Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), PepMix Pan-SARS-CoV-2 Select


  • Hepatitis E Virus Epidemiology and Vaccine Response: Studies from Norway and Bangladesh
    Øverbø, Dissertation (2023) 
    Product used: PepMix HEV (ORF2)
  • Ineffective control of Epstein-Barr-virus-induced autoimmunity increases the risk for multiple sclerosis
    Vietzen et al., Cell (2023) - PMID: 38091993
    Product used: PepMix™ Collection EBV 
  • Evaluation of Luciferase and Prefusion-Stabilized F Protein From Respiratory Syncytial Virus mRNA/LNPs in Pre-Clinical Models Using Jet Delivery Compared to Needle and Syringe
    Meyer et al., Vaccine (2023) 
    Product used: PepMix™ HRSVA (Fusion Glycoprotein F0)
  • The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy
    Lasagna et al., Human Vaccines & Immunotherapeutics (2023) - PMID: 38037900
    Products used: PepMix VZV (IE63), PepMix VZV (gE)
  • Interaction dynamics between innate and adaptive immune cells responding to SARSCoV-2 vaccination in non-human primates
    Schramm et al., Nature Communications (2023) - PMID: 38042809
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • Safety, immunogenicity and efcacy of an mRNA‑based COVID‑19 vaccine, GLB‑COV2‑043, in preclinical animal models
    Lelis et al., Scientific Reports (2023) - PMID: 38040905
  • Production, purification and immunogenicity of Gag virus-like particles carrying SARS-CoV-2 components
    Gashti et al., Vaccine (2023) - PMID: 38042697
    Product used: PepMix SARS-CoV-2 (NCAP)
  • Conjugation of HIV-1 envelope to hepatitis B surface antigen alters vaccine responses in rhesus macaques
    Nettere et al., Vaccines (2023) - PMID: 38001122
    Products used:  PepMix HBV (Large envelope protein), PepMix HIV-1 (ENV) Ultra
  • Associations of myeloid cells with cellular and humoral responses following vaccinations in patients with neuroimmunological diseases
    Wang et al., Nature Communications (2023) - PMID: 38007484
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • Impaired Cellular and Antibody immunity after COVID-19 in Chronically Immunosuppressed Transplant Recipients
    Ashokkumar et al., Journal of Surgery and Research (2023)
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB2)
  • Immunotherapy of cytomegalovirus infection by low-dose adoptive transfer of antiviral CD8 T cells relies on substantial post-transfer expansion of central memory cells but not effector-memory cells
    Holtappels et al., PLoS Pathogens (2023) 
    Product used: custom PepMix
  • Hydroxyurea interaction with α7 nicotinic acetylcholine receptor can underlie its therapeutic efficacy upon COVID-19
    Lykhmus et al., Neuroimmunology (2023) - PMID: 38016403
    Product used: custom PepMix
  • Concomitant administration of seasonal influenza and COVID-19 mRNA vaccines
    Aydillo et al., Emerging Microbes & Infections (2023) - PMID: 38054302
    Products used: PepMix Influenza A (HA/H1N1/Victoria/2019)Influenza A (HA/H3N2/Darwin/2021)custom PepMix Influenza B Nucleoprotein
  • A Phase I/II Clinical Trial of Intradermal, Controllable Self-Replicating Ribonucleic Acid Vaccine EXG-5003 against SARS-CoV-2
    Koseki et al., Vaccines (2023) 
    Product used: PepMix SARS-CoV-2 (S-RBD)
  • Efectiveness ofVSV vectored SARS‑CoV‑2 spike when administered through intranasal, intramuscular or a combination of both
    Beitari et al., Scientific Reports (2023) - PMID: 38049498
    Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
  • Tiza–Titre increase and enhanced immunity through an adjuvanted, recombinant herpes zoster subunit vaccine in patients with liver cirrhosis and post-liver transplantation: a study protocol for a prospective cohort study
    Vollmer-Raschdorf et al., BMJ Open (2023) 
    Product used: PepMix VZV (gE)
  • Caracterización del agotamiento de los linfocitos T en pacientes con síndrome Long COVID
    Benéitez, Thesis (2023) 
    Products used: PepMix Influenza A (HA/California (H1N1)), custom PepMix Influenza (HA/Perth (H3N2))
  • Cytomegalovirus-specific T cell immunity reconstitution following allogeneic hematopoietic stem cell transplantation: a pilot study
    Wang et al., Research Square (2023) 
    Products used: PepMix CMVA (IE-1), PepMix CMVA (pp65)
  • Immunogenicity of a silica nanoparticle-based SARS-CoV-2 vaccine in mice
    Barbey et al., European Journal of Pharmaceutics and Biopharmaceutics (2023) - PMID: 37774890
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 SUB2)
  • Impaired immune responses and prolonged viral replication in lung allograft recipients infected with SARS‑CoV‑2 in the early phase after transplantation
    Glueck et al., Infection (2023) - PMID: 37922037
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • Early humoral and cellular responses after bivalent SARS‐CoV‐2 mRNA‐1273.214 vaccination in long‐term care and retirement home residents in Ontario, Canada: An observational cohort study
    Breznik et al., Journal of Medical Virology (2023) - PMID: 37822054
    Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
  • Cytomegalovirus-Specific T Cells in Pediatric Liver Transplant Recipients
    Getsuwan et al., Viruses (2023) 
    Products used: PepMix CMVA (IE-1), PepMix CMVA (pp65)
  • Humoral and Cellular Immunity Are Significantly Affected in Renal Transplant Recipients, Following Vaccination with BNT162b2
    Fylaktou et al., Vaccines (2023) 
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy target
    Mandal et al., Nature Cancer (2023) 
    Products used: PepMix EBV (LMP1), PepMix EBV (EBNA1), PepMix EBV (LMP2), PepMix EBV (BZLF1), PepMix EBV (BRLF1), PepMix CMVA (pp65), PepMix CMVA (IE-1)
  • SARS-CoV-2 infection establishes a stable and age-independent CD8+ T cell response against a dominant nucleocapsid epitope using restricted T cell receptors
    Choy et al., Nature Communications (2023) - PMID: 37872153
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1)
  • Revaccination of patients with systemic lupus erythematosus or rheumatoid arthritis without an initial COVID-19 vaccine response elicits seroconversion in half of the patients
    Ammitzbøll et al., Clinical and Experimental Rheumatology (2023) - PMID: 37877429
  • An interferon-integrated mucosal vaccine provides pan-sarbecovirus protection in small animal models
    Yuen et al., Nature Communications (2023) - PMID: 37875475
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2
    Lázaro-Gorines et al., Advanced Science (2023) 
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • Immunology of THymectomy And childhood CArdiac transplant (ITHACA): protocol for a UK-wide prospective observational cohort study to identify immunological risk factors of post-transplant lymphoproliferative disease (PTLD) in thymectomised children
    Offor et al., BMJ Open (2023) - PMID: 37865406
    Products used: custom PepMix
  • T regulatory lymphocytes specific for SARS-CoV-2 display increased functional plasticity
    Esparcia-Pinedo et al., Clinical Immunology - PMID: 37827267
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), PepMix™ CMVA (pp65)
  • Immune Profile Determines Response to Vaccination against COVID-19 in Kidney Transplant Recipients
    Stai et al., Vaccines (2023) - PMID: 37896986
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • Cytokine profile of anti-spike CD4+T cells predicts humoral and CD8+T cell responses after anti-SARSCoV-2 mRNA vaccination
    Tartour et al., Research Square (2023) - PMID
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
  • Pretransplant BKV-IgG serostatus and BKV-specific ELISPOT assays to predict BKV infection after kidney transplantation
    Bae et al., Frontiers in Immunology (2023) - PMID: 37809095
    Products used: PepMix BKV (capsid protein VP1), PepMix BKV (capsid protein VP2), PepMix BKV (capsid protein VP2, isoform VP3)
  • An RNA-Scaffold Protein Subunit Vaccine for Nasal Immunization
    Lam et al., Vaccines (2023) - PMID: 37896953
    Product used: PepMix SARS-CoV-2 (S-RBD)
  • Selection of cross-reactive T cells by commensal and food-derived yeasts drives cytotoxic TH1 cell responses in Crohn’s disease
    Martini et al., Nature Medicine (2023) - PMID: 37749331
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • Preexisting Enhancing Antibodies in Vaccinated Participants Accelerate Dengue Virus 1 Infection Following Live Virus Human Challenge
    Lyke et al., Research Square (2023)  
    Product used: Custom PepMix
  • Enhanced Omicron subvariant cross-neutralization efficacy of a SARS-CoV-2 BA.4/5 mRNA vaccine encoding a noncleaved, nonfusogenic spike antigen
    Oh et al., Research Square (2023) 
    Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron)
  • Spontaneous HIV expression during suppressive ART is associated with the magnitude and function of HIVspecific CD4+ and CD8+ T cells
    Dubé et al., Cell Hosts Microbe (2023) - PMID: 37708853
    Products used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • Responses of patients with cancer to mRNA vaccines depend on the time interval between vaccination and last treatment
    Donhauser et al., Journal for ImmunoTherapy of Cancer - PMID: 37730271
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: A 20- month longitudinal study
    Hvidt et al., Research Square (2023) - PMID: 37974069
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • SARS-CoV-2 variants of concern elicit divergent early immune responses in hACE2 transgenic mice
    Fricke et al., European Journal of Immunology (2023) - PMID: 37609807
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • A cell-free antigen processing system informs HIV-1 epitope selection and vaccine design
    Sengupta et al., Journal of Experimental Medicine (2023) - PMID: 37058141
    Products used: PepMix HIV-1 (NEF) Ultra, HIV-1 (Con B gag motif)
  • Lymph node dendritic cells harbor inducible replication-competent HIV despite years of suppressive ART
    Banga et al., Cell Host & Microbe (2023) - PMID: 37751747
  • Ablative radiation alone in stage I lung cancer produces an adaptive systemic immune response: insights from a prospective study
    Voong et al., Journal for ImmunoTherapy of Cancer (2023) 
    Products used: CEFX Ultra SuperStim Pool MHC-II Subset & PepMix™ HIV-1 (GAG) Ultra
  • Enhancing Anti-SARS-CoV-2 Neutralizing Immunity by Genetic Delivery of Enveloped Virus-like Particles Displaying SARS-CoV-2 Spikes
    Yang et al., Vaccines (2023) 
    Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 SUB2)
  • Early Omicron infection is associated with increased reinfection risk in older adults in long-term care and retirement facilities
    Breznik et al., The Lancet (2023)
    Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
  • First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
    Thibaudin et al., Nature Medicine (2023) - PMID: 37563240
    Products used: PepMix Human (NY-ESO-1)
  • Intradermal administration of DNA vaccine targeting Omicron SARS‑CoV‑2 via pyro‑drive jet injector provides the prolonged neutralizing antibody production via germinal center reaction
    Hayashi et al., Scientific Reports (2023) - PMID: 37563266
    Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
  • Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing mice
    Dasari et al., Nature Communications (2023) - PMID: 37553346
    Products used: PepMix EBV (GP350/GP340)
  • Safety and immunogenicity of a SARS-CoV-2 Gamma variant RBD-based protein adjuvanted vaccine used as booster in healthy adults
    Pasquevich et al., Nature Communications (2023) 
    Product used: PepMix SARS-CoV-2 (S-RBD P.1 / Gamma)
  • Zika virus infection during pregnancy and vertical transmission: case reports and peptide-specic cellmediated immune responses
    Soudeyns et al., Research Sqaure (2023) 
    Products used: PepMix CMVA (pp65)ZIKV (NS1) UltraZIKV (C) UltraZIKV (E) Ultra
  • YF17D-vectored Ebola vaccine candidate protects mice against lethal surrogate Ebola and yellow fever virus challenge
    Lemmens et al., Vaccines (2023) 
    Product used: PepMix Zaire Ebola (GP/Kikwit-95)
  • Breadth and Durability of SARS-CoV-2-Specific T Cell Responses following Long-Term Recovery from COVID-19
    Dang et al., Microbiology Spectrum (2023) - PMID: 37428088
    Products used: PepMix SARS-CoV-2 (Spike Glycoprotein)SARS-CoV-2 (NCAP)SARS-CoV-2 (VEMP)SARS-CoV-2 (VME1)SARS-CoV-2 (ORF10)SARS-CoV-2 (ORF9B)
    Custom PepMix : SARS-CoV-2 ORF3a, ORF6, ORF7a, ORF7b, ORF8
  • A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammation
    Kimura et al., Molecular Therapy (2023) - PMID: 37403357
    Product used: PepMix™ SARS-CoV-2 (Spike B.1.351 / Beta)
  • Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responses
    Hellgren et al., Nature Communications (2023) - PMID: 37349310
    Product used: PepMix Rabies virus (Glycoprotein)
  • Immunological imprinting of humoral immunity to SARS-CoV-2 in children
    Dowell et al., Nature Communications - PMID: 37386081
    Product used: PepMix™ SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron) & Influenza A (MP1 (H3N2))
  • Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines
    Han et al., Nature Nanotechnology (2023) - PMID: 37365276
    Products used: PepMix™ SARS-CoV-2 (S-RBD)
  • Characterization of T cell responses to SARS-CoV-2 following infection and vaccination
    Law, Dissertation (2023)
    Products used: PepMix™SARS-CoV-2 (VME1)SARS-CoV-2 (VEMP), SARS-CoV-2 (NCAP) & SARS-CoV-2 (Spike Glycoprotein SUB1 SUB2)
  • Oligosymptomatic long-term carriers of SARS-CoV-2 display impaired innate resistance but increased high-affinity anti-Spike antibodies
    Montes-Cobos et al., iScience (2023) 
    Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
  • Early evaluation of the safety, reactogenicity, and immune response after a single dose of modified vaccinia Ankara–Bavaria Nordic vaccine against mpox in children: a national outbreak response
    Ladhani et al., The Lancet (2023) - PMID: 37336224
    Product used: Custom PepMix
  • Third and Fourth Vaccine Doses Broaden and Prolong Immunity to SARSCoV-2 in Adult Patients with Immune-Mediated Inammatory Diseases
    Cheung et al., Journal of Immunology (2023) - PMID: 37326480
    Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron)
  • T-Cell-Dominated Immune Response Resolves Protracted SARS-CoV-2 Infection in the Absence of Neutralizing Antibodies in an Immunocompromised Individual
    Bunse et al., Microorganisms (2023) - PMID: 37375064
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 SUB2)
  • Engineered tumor-specific T cells using immunostimulatory photothermal nanoparticles
    Sweeney et al., Cytotherapy (2023) - PMID: 37278683
    Products used: custom PepMix
  • High efficacy of VLA2001 vaccine against SARSCoV-2 infection in non-human primates
    Le Grand et al., Research Square (2023) 
    Products used: PepMix™ SARS-CoV-2 (S-RBD) & SARS-CoV-2 (NCAP)
  • A novel multi-antigenic parapoxvirus-based vaccine demonstrates efficacy in protecting hamsters and non-human primates against SARS-CoV-2 challenge
    Reguzova et al., Research Square et al., (2023) 
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP)
  • The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus
    Brzuska et al., Microbiology Spectrum (2023) - PMID: 37199661
    Product used: PepMix™ SARS-CoV-2 (S-RBD)
  • The effects of exercise training for eight weeks on immune cell characteristics among breast cancer survivors
    Echarri et al., Frontiers Sports Act. Living (2023) - PMID: 37252426
    Product used: PepMix™ CMVA (pp65) VZV (IE63)
  • Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy
    Macková et al., Leukemia Research (2023) - PMID: 37216792
    Product used: PepMix™ SARS-CoV-2 (NCAP)
  • Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in Peoplen with HIV
    Verburgh et al., Microbiology Spectrum (2023) - PMID: 37166335
    Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) SARS-CoV-2 (NCAP)
  • A protective, single-visit TB vaccination regimen by co-administration of a subunit vaccine with BCG
    Dijkman et al., Vaccines (2023) - PMID: 37160970
    Product used: PepMix M. tuberculosis (ESAT-6)M. tuberculosis (PPE68)M. tuberculosis (EspA)PepMix M. tuberculosis (MPT64) & custom PepMix (for EspI, EspC, MPT70, MPT83), 
  • Pre-pandemic SARS-CoV-2-specific IFN-γ and antibody responses were low in Ugandan samples and significantly reduced in HIV-positive specimens
    Nantambi et al., Frontiers in Immunology (2023) - PMID: 37153598
    Product used: PepMix™ SARS-CoV-2 (Spike Glycoproteins)
  • High-dimensional analysis of 16 SARS-CoV-2 vaccine combinations reveals lymphocyte signatures correlating with immunogenicity
    Nuñez et al., Nature Immunology (2023) - PMID: 37095378
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP)
  • Impact of age and comorbidities on SARS-CoV-2 vaccine-induced T cell immunity
    Dietz et al., Communications Medicine (2023) - PMID: 37095240
    Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
  • ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines
    Hoffmann et al., Cell (2023) - PMID: 37146611
    Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
  • COVID-19 relapse associated with SARS-CoV-2 evasion from CD4+ T-cell recognition in an agammaglobulinemia patient
    Morita et al., iScience (2023) - PMID: 37124420
    Products used: 27 structural and non-structural PepMix SARS-CoV-2 proteins
  • Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy
    Sharma et al., Journal for Immunotherapy of Cancer (2023) - PMID: 37072346
    Product used: PepMix™ EBV (EBNA1)EBV (LMP1)EBV (LMP2) & EBV (BARF1)
  • Exercise mobilizes diverse antigen specific T-cells and elevates neutralizing antibodies in humans with natural immunity to SARS CoV-2
    Baker et al., Brain, Behaviour & Immunity (2023) - PMID:  36743994
    Products used: PepMix™ Human (Actin) & SARS-CoV-2 (Spike Glycoprotein)
  • A cell-free antigen processing system informs HIV-1 epitope selection and vaccine design
    Sengupta et al., Journal of Experimental Medicine (2023) - PMID: 37058141
    Product used: PepMix™ HIV-1 (NEF) Ultra HIV-1 (Con B gag motif)
  • Long-Term Follow-Up after Adoptive Transfer of BK-Virus-Specific T Cells in Hematopoietic Stem Cell Transplant Recipients
    Koldehoff  et al., Vaccines (2023) - PMID: 37112757
    Product used: PepMix™ BKV (capsid protein VP1) BKV (large T antigen)
  • Metabolic interventions improve HBV envelope-specific T-cell responses in patients with chronic hepatitis B
    Fu et al., Hepatology International (2023) - PMID: 36976426
    Product used: PepMix™ HBV (Capsid Protein) Ultra & HBV (LEP) Ultra
  • Omicron BA.4/5 neutralization and T-cell responses in organ transplant recipients after Booster mrna vaccine: a Multicenter Cohort Study
    Ferreira et al., Clinical Infectious Diseases (2023) - PMID: 36975097
    Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron)
  • Cytotoxic T Cells Targeting Spike Glycoprotein Are Associated with Hybrid Immunity to SARS-CoV-2
    Phan et al., Journal of Immunology (2023) - PMID: 36961450
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP)
  • Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical models
    Saeland et al., Vaccines (2023) - PMID: 36949051
    Product used: PepMix HRSVA (Fusion Glycoprotein F0)
  • Humoral and cellular immunity to SARS-CoV-2 after vaccination with mRNA vaccines in PLWH with discordant immune response. Influence on the vaccine administered
    López-Cortés et al., Frontiers in Immunology (2023) - PMID: 37006309
    Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
  • SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodies
    Shrivastava et al., Vaccines (2023) - PMID: 36934088
    Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
  • Immunogenicity of COVID-eVax Delivered by Electroporation Is Moderately Impacted by Temperature and Molecular Isoforms
    D'Alessio et al., Vaccines (2023) - PMID: 36992261
    Product used: PepMix™ SARS-CoV-2 (S-RBD)
  • Spezifische T-Zellantwort und Immunevasion beim humanen Herpesvirus 6 und SARS-CoV-2
    Hollaus, Dissertation (2023)
  • Engineering potent live attenuated coronavirus vaccines by targeted inactivation of the immune evasive viral deubiquitinase
    Myeni et al., Nature Communications (2023) 
    Product used: PepMix MERS-CoV (Spike Glycoprotein)
  • Schistosoma mansoni infection alters the host pre-vaccination environment resulting in blunted Hepatitis B vaccination immune responses.
    Muir et al., MedRxiv (2023) 
    Product used: PepMix HBV (Large envelope protein)
  • A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines
    Ryan et al., Cell Reports Medicine (2023) 
    Product used: PepMix Chimpanzee Adenovirus Y25 (Hexon Protein)
  • Incorporation of SARS-CoV-2 spike NTD to RBD Protein Vaccine Improves Immunity Against Viral Variants
    Montgomerie et al., IScience (2023) 
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • Pyrimidine de novo synthesis inhibition selectively blocks effector but not memory T cell development
    Scherer et al., Nature Immunology (2023) 
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice
    Nanishi et al., Vaccines (2023) 
    Product used: PepMix SARS-CoV-2 (S-RBD)
  • Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models
    Corleis et al., Nature Communications (2023) 
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • The role of the T-cell mediated immune response to Cytomegalovirus infection in intrauterine transmission
    Soriano-Ramos et al., PLOS One (2023) 
    Products used: PepMix CMVA (IE-1) & CMVA (pp65)
  • Multimodal single‑cell analyses of peripheral blood mononuclear cells of COVID‑19 patients in Japan
    Kashima et al., Scientific Reports (2023) - PMID: 36732528
    Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), SARS-CoV-2 (VEMP), SARS-CoV-2 (VME1), ....ORF3a/6/7a/7b/8/9b/10
  • Trimeric, APC-Targeted Subunit Vaccines Protect Mice against Seasonal and Pandemic Influenza
    Tjärnhage et al., Journal of Virology (2023) 
    Products used: PepMix Influenza A (HA/Puerto Rico/8/1934 H1N1) & Influenza A (HA /California (H1N1))
  • Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies
    Gressens et al., Vaccines (2023) 
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 SUB2)
  • Long COVID manifests with T cell dysregulation, inflammation, and an uncoordinated adaptive immune response to SARS-CoV-2
    Yin et al., BioRxiv (2023) 
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • Exercise mobilizes diverse antigen specific T-cells and elevates neutralizing antibodies in humans with natural immunity to SARS CoV-2
    Baker et al., Brain Behaviour & Immunity - Health (2023) 
    Products used: PepMix Human (Actin) & SARS-CoV-2 (Spike Glycoprotein)
  • The HDAC inhibitor zabadinostat is a systemic regulator of adaptive immunity
    Liu et al., Communications Biology (2023)
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • SARS-CoV-2 Omicron BA.4/BA.5 Mutations in Spike Leading to T Cell Escape in Recently Vaccinated Individuals
    Emmelot et al., Viruses (2023)
  • Immunogenicity and safety of a two-dose regimen with hepatitis E virus vaccine in healthy adults in rural Bangladesh: A randomized, double-blind, controlled, phase 2/pilot trial
    Øverbø et al., Vaccine (2023) 
    Product used: PepMix HEV (ORF2)
  • A linear DNA encoding the SARS-CoV-2 receptor binding domain elicits potent immune response and neutralizing antibodies in domestic cats
    Conforti et al., Molecular Therapy (2023) 
    Product used: PepMix SARS-CoV-2 (S-RBD)
  • Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A Prospective double-blind randomised hase III clinical study
    Thuluva et al., MedRxiv (2023)
    Product used: PepMix SARS-CoV-2 (S-RBD)
  • The prospect of universal coronavirus immunity: a characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses
    Soni et al., BioRxiv (2023)
  • Assessment of Immunogenicity and Efficacy of CV0501 mRNA-based Omicron COVID-19 Vaccination in Small Animal Models
    Roth et al., BioRxiv (2023)
    Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
  • Diminished responses to mRNA-based SARS-CoV-2 vaccines in individuals with rheumatoid arthritis on immune modifying therapies
    Klebanoff et al., MedRxiv (2023) 
    Products used: CEFX Ultra SuperStim Pool, PepMix SARS-CoV-2 (Spike Glycoprotein)
  • An inactivated SARS-CoV-2 vaccine induced cross-neutralising persisting antibodies and protected upon challenge in small animals
    Offersgaard et al., iScience (2023)
    Products used: SARS-CoV-2 (Spike Glycoprotein)SARS-CoV-2 (S-RBD)SARS-CoV-2 (NCAP), SARS-CoV-2 (Spike Glycoprotein SUB1 SUB2)
  • Safety, tolerability, and immunogenicity of a new SARS-CoV-2 recombinant Gamma variant RBD-based protein adjuvanted vaccine, used as heterologous booster in healthy adults: a Phase 1 interim report
    Pasquevich et al., MedRxiv (2023)
    Product used: PepMix SARS-CoV-2 (S-RBD P.1 / Gamma)
  • Single-dose YF17D-vectored Ebola vaccine candidate protects mice against both lethal surrogate Ebola and yellow fever virus challenge
    Lemmens et al., BioRxiv (2023)
    Products used: PepMix Zaire Ebola (GP/Kikwit-95)Yellow fever (NS4B)


  • Persistence of SARS-CoV-2 neutralizing antibodies and anti-Omicron IgG induced by BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic disease: An explanatory study in Japan
    Yamaguchi et al., The Lancet (2023) 
    Product used: PepMix SARS-CoV-2 (Spike), SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
  • Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma
    Keppler-Hafkemeyer et al., Nature Cancer (2023) - PMID: 36543907
    Products used: PepMix SARS-CoV-2 (Spike B.1.617.2 / Delta)Human Adenovirus 5 (Hexon Protein)HCoV-OC43 (Spike Glycoprotein)SARS-CoV-2 (NCAP)
  • Listeria-vectored multi-antigenic tuberculosis vaccine protects C57BL/6 and BALB/c mice and guinea pigs against Mycobacterium tuberculosis challenge
    Jia et al., Communications Biology (2022) 
    Products used: PepMix M. tuberculosis (Ag85B), M. tuberculosis (EspA)M. tuberculosis (EsxN)M. tuberculosis (TB8.4)M. tuberculosis (MPT64), custom PepMix (EsxH, EsxB, EsxA, ppe68)
  • A novel intradermal tattoo-based injection device enhances the immunogenicity of plasmid DNA vaccines
    Gomez et al., Vaccines (2022) - PMID: 36543794
    Products used: PepMix Zaire Ebola (GP/Mayinga-76)
  • Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators
    Sabatino et al., Multiple Sclerosis and Related Disorders (2022) 
    Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 SUB2)
  • Comprehensive Analysis of Epstein-BarrVirus LMP2A-Specific CD8+ and CD4+ T Cell Responses Restricted to Each HLA Class I and II Allotype Within an Individual
    Jo et al., Immune Network (2022) 
    Product used: PepMix EBV (LMP2)
  • Accelerated waning of immune responses to a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases
    Mrak et al., Journal of Autoimmunity (2022) 
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
  • Characterization of Three Variants of SARS-CoV-2 In Vivo Shows Host-Dependent Pathogenicity in Hamsters, While Not in K18-hACE2 Mice
    Toomer et al., Viruses (2022) - PMID: 36423193
  • Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
  • High antibody levels and reduced cellular response in children up to one year after SARS-CoV-2 infection
    Jacobsen et al., Nature Communications (2022) 
    Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
  • Allogeneic, Off-the-Shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high risk patients
    Vasileiou et al., Haemtologica (2022) 
    Products used: PepMix SARS-CoV-2 (NCAP)SARS-CoV-2 (VME1)SARS-CoV-2 (VEMP)SARS-CoV-2 (Spike Glycoprotein)SARS-CoV-2 (NS7A)SARS-CoV-2 (NS7B)SARS-CoV-2 (NS8)
  • SARS-CoV-2-Spike Antibody and T-Cell Responses Elicited by a Homologous Third mRNA COVID-19 Dose in Hemodialysis and Kidney Transplant Recipients
    Panizo et al., Microorganisms (2022) 
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 SUB2)
  • Combined plasma cell-free DNA detection and IFNγ/TNF-α dual fluorospot assays for diagnosing active tuberculosis
    Kim et al., Research Square (2022)
    Products used: PepMix M. tuberculosis (ESAT-6)M. tuberculosis (CFP-10)M. tuberculosis (Ag85B)
  • Four-Parameter FluoroSpot Assay Reveals That the Varicella Zoster Virus Elicits a Robust Memory T Cell IL-10 Response throughout Childhood
    Nilsson et al., Journal of Virology (2022) - PMID: 36314824
    Products used: PepMix VZV (IE63) & VZV (gE)
  • Characterization of B-cell and T-cell responses to a tetravalent dengue purified inactivated vaccine in healthy adults
    Friberg et al., Vaccines (2022) - PMID: 36316335
    Product used: PepMix Dengue 1 (E) Ultra
  • Reduced humoral but stable cellular SARS-CoV-2-specific immunity in liver transplant recipients in the first year after COVID-19
    Kirchner et al., PLoS One (2022) - PMID: 36322587
    Products used: PepMix Pan-SARS-CoV-2 Select, SARS-CoV-2 (Spike Glycoprotein SUB1 SUB2), SARS-CoV-2 (NCAP)SARS-CoV-2 (VEMP)HCoV-229E (Spike Glycoprotein)HCoV-OC43 (Spike Glycoprotein)HRSVB (Nucleocapsid Protein N)Influenza A (M1) Ultra
  • Efficacy of mucosal vaccination using a protozoan parasite as a vehicle for antigen delivery: IgG and neutralizing response after rectal administration of LeCoVax-2, a candidate vaccine against COVID-19
    Epis et al., Pharmacological Research (2022) - PMID: 36336215
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • Immunological signature in human cases of monkeypox infection in 2022 outbreak: an observational study
    Agrati et al., The Lancet (2022)
    Products used: PepMix Vaccinia virus (MVA105L)Vaccinia virus (MVA074R)Vaccinia virus (MVA121L)
  • SARS-CoV-2 Spike-specific IFN-gamma T-cell Response After COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant
    Imhof et al., Infectious Disease (2022) 
    Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 SUB2)
  • Chimeric mRNA based COVID-19 vaccine induces protective immunity against Omicron and Delta variants
    Hu et al., Molecular Therapy (2022) 
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • Humoral and Cellular Responses to a Delayed Fourth SARS-CoV-2 mRNA-Based Vaccine in Weak Responders to 3 Doses Kidney Transplant Recipients
    Del Bello et al., Vaccines (2022) - PMID: 36146517
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 SUB2)
  • A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses
    Lenart et al., Molecular Therapy (2022) 
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • A Tale Of T ale Of Two Transgenes: Aa ansgenes: Aav-Dystr v-Dystrophin And Aa ophin And Aav-Spike Reveal Common Themes For Gene Therapy And Vaccines
    Greer, Dissertation (2022) 
    Products used: PepMix SARS-CoV-2 (Spike Glycoprotein) and SARS-CoV-2 (Spike B.1.1.7 / Alpha)
  • Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern
    Akache et al., Vaccines (2022) 
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • Artificial Cell Membrane Polymersome-Based Intranasal Beta Spike Formulation as a Second Generation Covid-19 Vaccine
    Lam et al., ACS Nano (2022) -
    Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 SUB2)
  • Signs of immunosenescence correlate with poor outcome of mRNA COVID-19 vaccination in older adults
    Palacios-Pedrero et al., Nature Aging (2022) 
    Product used: PepMix SARS-CoV-2 (NCAP)
  • Rekombinowane cząstki wirusopodobne jako potencjalne antygeny szczepionkowe przeciwko wirusowi Zika
    Brzuska, Dissertation (2022)
    Products used: PepMix ZIKV (E) Ultra and ZIKV (M) Ultra
  • Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial
    Gunst et al., Nature Medicine (2022) - PMID: 36253609
    Product used: PepMix HIV Gag Ultra
  • NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens
    Hielscher et al., Journal of Clinical Virology (2022) - PMID: 36279695
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • Immune Response after the Fourth Dose of SARS-CoV-2 mRNA Vaccine Compared to Natural Infection in Three Doses’ Vaccinated Solid Organ Transplant Recipients
    Busà et al., Vaccines (2022) - PMID: 36298854
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)SARS-CoV-2 (NCAP) and CEFX Ultra SuperStim Pool
  • Proinflammatory Innate Cytokines and Distinct Metabolomic Signatures Shape the T Cell Response in Active COVID-19
    Binayke et al., Vaccines (2022) - PMID: 36298628
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 SUB2)
  • Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose
    Belik et al., Research Square (2022) 
    Products used: PepMix SARS-CoV-2 (Spike Glycoprotein)SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron), and SARS-CoV-2 (Spike B.1.1.529 / BA.2 / Omicron)
  • Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity
    Rosás-Umbert et al., Nature Communications (2022)
    Products used: PepMix HIV-1 (GAG) UltraHIV-1 (ENV) UltraHIV-1 (NEF) UltraHIV-1 (POL) Ultra
  • Ablation of CD8+ T cell recognition of an immunodominant epitope in SARS-CoV-2 Omicron variants BA.1, BA.2 and BA.3
    Swaminathan et al., Nature Communications 
    Products used: PepMix SARS-CoV-2 (NCAP)SARS-CoV-2 (NS6), SARS-CoV-2 (NS7A)SARS-CoV-2 (NS7B)SARS-CoV-2 (NS8)SARS-CoV-2 (ORF9B), SARS-CoV-2 (ORF10)SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (VEMP)SARS-CoV-2 (VME1)SARS-CoV-2 (Y14)
  • Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infection
    Khatamzas et al., Nature Communication (2022)
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • Evidence of premature lymphocyte aging in people with low anti-spike antibody levels after BNT162b2 vaccination
    Huang et al., iScience (2022) - PMID: 
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • SARS-CoV-2-specicific humoral immunity in convalescent patients with mild COVID-19 is supported by CD4+ T-cell help and negatively correlated with Alphacoronavirus-specific antibody titer
    Odendahl et al., Immunology Letters (2022) 
    Product used: PepMix CMVA (pp65)
  • Comparison of the Immune Responses to COVID-19 Vaccines in Bangladeshi Population
    Sarker et al., Vaccines (2022) 
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • Comparison between enzyme‐linked immunospot assay and intracellular cytokine flow cytometry assays for the evaluation of T cell response to SARS‐CoV‐2 after symptomatic COVID‐19
    Villemonteix et al., Immunity, Inflammation and Disease (2022) - PMID
    PepMix SARS-CoV-2 (Spike Glycoprotein)SARS-CoV-2 (NCAP)
  • Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models
    Hajnik et al., Science Translational medicine (2022) - PMID: 36103514
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection
    Ao et al., Journal of Virology (2022) - PMID: 36069551
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1)
  • SARS-CoV-2 mRNA-vaccine candidate; COReNAPCIN, induces robust humoral and cellular immunity in mice and non-human primates
    Alimohammadi et al., Vaccines (2022) - PMID: 36056015
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • SARS‑CoV‑2‑reactive IFN‑γ‑producing CD4+ and CD8+T cells in blood do not correlate with clinical severity in unvaccinated critically ill COVID‑19 patients
    Olea et al., Scientific Reports (2022) - PMID: 35995830
  • Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response
    Stort et al., Oncoimmunology (2022) 
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment
    Su et al., ESMO Open (2022)
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • Protective Immunity of COVID-19 Vaccination with ChAdOx1 nCoV-19 Following Previous SARS-CoV-2 Infection: A Humoral and Cellular Investigation
    Azamor et al., Viruses (2022) - PMID: 36146723
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors
    Lu et al., Clinical Immunology (2022) 
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an openlabel extension study
    Mrak et al., Annals of Rheumatic Disease (2022) - PMID: 35977809
  • Gene Transfer in Adeno-Associated Virus Seropositive Rhesus Macaques Following Rapamycin Treatment and Subcutaneous Delivery of AAV6, but Not Retargeted AAV6 Vectors
    Stone et al., Human Gene Therapy (2022)
  • SARS-CoV-2-specific CD4+ T cell longevity correlates with Th17-like phenotype
    Terahara et al., iScience (2022) - PMID: 35992306
  • Japanese encephalitis virus infection in its natural amplification and reservoir host, the pig
    Redant, Dissertation (2022) 
  • Secreted heat shock protein gp96-Ig and OX40L-Fc combination vaccine enhances SARS-CoV-2 Spike (S) protein-specific B and T cell immune responses
    Padula et al., Vaccine: X (2022) - PMID: 35936992
    Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SU1 & SU2)
  • Analysis of the Specific Immune Response after the Third Dose of mRNA COVID-19 Vaccines in Organ Transplant Recipients: Possible Spike-S1 Reactive IgA Signature in Protection from SARS-CoV-2 Infection
    Miele et al., Microorganisms (2022)
    Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SU1 & SU2) & SARS-CoV-2 NCAP
  • mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
    Nanishi et al., Communications Biology (2022) 
  • Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose
    Renia et al., Nature Communications
  • The long term vaccine-induced anti-SARS-CoV-2 immune response is impaired in quantity and qualityunder TNFα blockade
    Geisen et al.,  Journal of Medical Virology (2022) - PMID: 35945627
  • Clinical outcomes, immunogenicity, and safety of BNT162b22 Vaccine in Primary Antibody Deficiency
    Milota et al., Authorea (2022) 
  • DNA-Vaccine-Induced Immune Response Correlates with Lower Viral SARS-CoV-2 Titers in a Ferret Model
    Compagnone et al., Vaccines (2022) - PMID: 35893826
  • SARS-CoV-2 Vaccine-Induced Antibody and T-Cell Response in SARS-CoV-1 Survivors
    Duan et al., Cell Reports (2022) 
  • Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA1273-boosting with homologous COVID-19 vaccine regimens
    Klemis et al., Nature Communications (2022) 
  • Brief Research Report: Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 Vaccination
    Sistere-Oro et al., Frontiers in Immunology (2022) 
  • Analysis of the humoral and cellular response after the third COVID-19 vaccination in patients with autoimmune hepatitis
    Hartl et al., Liver International (2022) - PMID: 35840342
  • Respiratory mucosal immunity against SARS-CoV-2 following mRNA vaccination
    Tang et al., Science Immunology (202) - PMID: 35857583
  • Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies
    Minnar et al., Journal of Immunology (2022) - PMID: 35764364
    Product used: PepMix HPV 16 (E7)
  • Robust SARS-COV-2-specific T-cell immune memory persists long-term in immunocompetent individuals post BNT162b2 double shot
    Papadopoulou et al., Heliyon (2022) - PMID: 35815135
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • A novel SARS-CoV-2 subunit vaccine engineered on an immune-activating platform technology
    Quinlan et al., Human Vaccines & Immunotherapeutics (2022) - PMID: 35801956
    Product used: PepMix SARS-CoV-2 (Spike-RBD)
  • Safety and immunogenicity of intramuscular, single- dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double- blind, placebo-controlled, dose-ranging trial
    Robbins et al., The Lancet (2022)
    Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  • A Lymph Node Targeted Adjuvant and Engineered Subunit Vaccine Promotes Potent Immunity to Epstein-Barr Virus in HLA-expressing Mice
    Dasari et al., Research Square (2022)
    Product used: PepMix EBV (GP350/GP340)
  • Longitudinal T Cell Responses against Ancestral, Delta, and Omicron SARS-CoV-2 Variants determined by Rapid Cytokine Release Assay in Whole Blood
    Oliver et al., Immunohorizons (2022) - PMID: 35750357
    Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SU1 & SU2), SARS-CoV-2 (Spike B.1.617/Delta),  SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
  • Long-Lived Immunity in SARS-CoV-2-Recovered Children and Its Neutralizing Capacity Against Omicron
    Sieber et al., Frontiers in Immunology (2022) - PMID: 35663948
    Product used: PepMix SARS-CoV-2 (VME1)SARS-CoV-2 (VEMP)SARS-CoV-2 (NCAP),  SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
  • Natural Immunity against HIV-1: Progression of Understanding after Association Studies
    Ma Luo, Viruses (2022) 
    Product used: PepMix HIV-1 (GAG) Ultra
  • In Vitro Generation of BK polyomavirus-specifc T cells for adoptive cell therapy in refractory cystitis hemorrhagic patients after hematopoietic stem cell transplantation
    Najafabadi et al., BMC Immunology (2022) - PMID: 35689183
    Product used: PepMix BKV (Capsid Protein VP1)
  • In Vitro Generation of BK polyomavirus-specifc T cells for adoptive cell therapy in refractory cystitis hemorrhagic patients after hematopoietic stem cell transplantation
  • Najafabadi et al., BMC Immunology (2022) - PMID: 35689183
    Product used: 
  • T-cell proliferation assay for the detection of SARS-CoV-2-specific T-cells
    Chu et al., Clinical Chimica Acta (2022) - PMID: 35690083
    Products used: PepMix SARS-CoV-2 (Spike Glycoprotein)SARS-CoV-2 (NCAP)SARS-CoV-2 (VME1)
  • Pre-existing adaptive immunity to the RNA-editing enzyme Cas13d in humans
    Tang et al., Nature Medicine (2022) - PMID: 35668177
    Product used: PepMix S. pyogenes (CAS9)_2 subpools
  • A DNA vaccine candidate delivered by an electroacupuncture machine provides protective immunity against SARS-CoV-2 infection
    Tzeng et al., Vaccines (2022)
  • Chimeric Virus-like Particle-Based COVID-19 Vaccine Confers Strong Protection against SARS-CoV-2 Viremia in K18-hACE2 Mice
    Kaewborisuth et al., Vaccines (2022)
  • Cellular Immune Response after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
    Koldehoff et al., Vaccines (2022)
  • SARS-CoV-2 OmicronBA.1 variantbreakthrough infections in nursing home residentsafter an homologousthird dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protection
    Torres et al., Journal of Medical Virology (2022) 
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
  • Durable immunogenicity, adaptation to emerging variants and low dose efficacy of AAV-based COVID19 platform in macaques
    Zabaleta et al., Molecular Therapy (2022)
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 SUB2)
  • Enhanced Humoral Immune Response After COVID-19 Vaccination in Elderly Kidney Transplant Recipients on Everolimus Versus Mycophenolate Mofetil–containing Immunosuppressive Regimens
    de Boer et al., Translantation (2022) - PMID: 35546527
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 SUB2)
  • SARS-CoV2 wild type and mutant specific humoral and T cell immunity is superior after vaccination than after natural infection
    Richardson et al., PLoS One (2022) - PMID: 35468147
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)SARS-CoV-2 (Spike B.1.1.7 / Alpha)SARS-CoV-2 (Spike B.1.351 / Beta)SARS-CoV-2 (Spike P.1 / Gamma), SARS-CoV-2 (Spike B.1.617.2 / Delta)
  • Two DNA vaccines protect against severe disease and pathology due to SARS-CoV-2 in Syrian hamsters
    Babuadze et al., NPJ Vaccines (2022) - PMID: 35474311
    Product used: PepMix™ SARS-CoV (Spike Glycoprotein)
  • Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2 Specific T cell therapy products
    Durkee-Shock et al., Molecular Therapy: Methods & Clinical Development (2022) 
  • Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod
    Cabeza et al., Neurology: Neuroimmunology & Neuroinflammation - PMID: 35523569
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 SUB2)
  • Children and Adults With Mild COVID-19: Dynamics of the Memory T Cell Response up to 10 Months
    Kaaijk et al., Frontiers in Immunology (2022) 
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)SARS-CoV-2 (NCAP)HCoV-OC43 (Spike Glycoprotein)
  • Strong peak immunogenicity but rapid antibody waning following third vaccine dose in elderlyresidents of care homes
    Tut et al., Research Square (2022) 
    Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
  • Discordant antibody and T cell responses to the SARS-CoV-2 Omicron variant in COVID-19 mRNA vaccine recipient
    Woldemeskel et al., Clinical Infectious Diseases (2022) - PMID: 35438751
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (S-RBD B.1.1.529 / Omicron)
  • USA SARS-CoV-2 Epsilon Variant: Though Highly Transmissible has an Adjusted Muted Host T-Cell Response
    Plummer et al., Clinical Infectious Diseases (2022) - PMID: 35438777
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) SARS-CoV-2 (Spike B.1.429 / Epsilon)
  • mRNA booster vaccination protects extremely aged mice against the SARS-CoV-2 Omicron variant
    Dowling et al., Research Square (2022) 
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) SARS-CoV-2 (S-RBD B.1.1.529 / Omicron)
  • Evaluation of overcoming Limited migration and Enhancing Cytomegalovirus-specific dendritic cell Vaccines with Adjuvant TEtanus pre-conditioning in patients with newlydiagnosed glioblastoma
    Randazzo et al., Clinical Trials (2022)
    Product used: PepMix™ CMVA (pp65) 
  • Viral Evolution and Immunology of SARS-CoV-2 in a Persistent Infection after Treatment with Rituximab
    van der Moerden et al., Viruses (2022) 
  • Dynamics of SARS-CoV-2-Spike-reactive antibody and T-cell responses in chronic kidney disease patients within three months after COVID-19 full vaccination
    Panizo et al., Clinical Kidney Journal (2022) 
    Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
  • Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): a single blind, randomized, non-inferiority trial
    Pannus et al., MedRxiv (2022)
  • Safety and tolerability of AAV8 delivery of abroadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial
    Casazza et al., Nature Medicine (2022) - PMID: 35411076
    Product used: PepMix™ AAV8 (capsid protein)
  • NK cells limit therapeutic vaccine–induced CD8+ T cell immunity in a PD-L1–dependent manner
    Diniz et al., Vaccines (2022) - PMID : 35417187
  • Temporal changes in T cell subsets and expansion of cytotoxic CD4+ T cells in the lungs in severe COVID-19
    Kaneko et al., Clinical Immunology (2022) - PMID: 35364330
    Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
  • T cell response against SARS-CoV-2 persists after one year in patients surviving severe COVID-19
    Venet et al., EBioMedicine (2022) - PMID: 35349827
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)SARS-CoV-2 (NCAP)SARS-CoV-2 (VME1)
  • CD4+ T Cell Dysfunction in Severe COVID-19 Disease is TNFalpha/TNFRI-Dependent
    Popescu et al., American Journal of Respiratory Critical Care Medicine - PMID: 35348444
    Products used: PepMix™ SARS-CoV-2 (NCAP)SARS-CoV-2 (VEMP), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
  • The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors
    Kroemer et al., Front Public Health (2022) - PMID: 35372242
    Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)SARS-CoV-2 (NCAP)SARS-CoV-2 (VME1)
  • High antibody and reduced cellular response in children up to one year after SARS-CoV-2 infection
    Jacobsen et al., Research Square (2022) 
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
  • Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study
    Lim et al., Nature Cancer (2022) - PMID : 35332334
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
  • Self-amplifying mRNA SARS-CoV-2 vaccines raise cross-reactive immune response to variants and prevent infection in animal models
    Palladino et al., Methods and Clinical Development (2022)
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP) 
  • Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine
    Gallais et al., Frontiers in Immunology (2022) - PMID: 35281046
    Products used: PepMix™ SARS-CoV-2 (Spike B.1.1.7 / Alpha)SARS-CoV-2 (Spike B.1.351 / Beta), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
  • SARS‐CoV‐2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease
    Duengelhoef et al., United European Gastroenterol Journal (2022) - PMID: 35289983
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
  • Novel T cell interferon gamma release assay (IGRA) using spike recombinant protein for COVID19 vaccine response and Nucleocapsid for SARS-Cov2 response
    Renaudineau et al., Clinical Immunology (2022) - PMID: n.a.
    Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
  • Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination
    Sheng et al., Journal of the Formosan Medical Association (2022) - PMID: 35305895
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
  • Modular capsid decoration boosts adenovirus vaccine-induced humoral and cellular immunity against SARS-CoV-2
    Dicks et al., BioRxiv (2022)
    Products used: PepMix™ SARS-CoV-2 (S-RBD)SARS-CoV-2 (Spike Glycoprotein)
  • SARS-CoV- 2 (COVID- 19)-specific T cell and B cell responses in convalescent rheumatoid arthritis: Monozygotic twins pair case observation
    Arruda et al., Immunology (2022) - PMID: 35212005
    Products used: PepMix™ SARS-CoV-2 (NCAP) SARS-CoV-2 (Spike Glycoprotein)
  • Humoral and Cellular Immune Responses of Solid Organ Transplant Patients on Belatacept to Three Doses of mRNA-Based Anti-SARS-CoV-2 Vaccine
    Abravanel et al., Vaccines (2022) 
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
  • Three-month follow-up of heterologous vs homologous third vaccination in kidney transplant recipients
    Heinzel et al., MedRxiv (2022)
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
  • Limited Recognition of Highly Conserved Regions of SARS-CoV-2
    Swaminathan et al., Microbiology Spectrum (2022) - PMID: 35196796
    Products used: PepMix™ SARS-CoV-2 (Nsp12)SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP)
  • Assessment of humora land cellular immune responses to SARSCoV-2 vaccination (BNT162b2) inimmunocompromised renal allograft recipients
    Zhang et al., Transplant Infectious Diseases (2022)
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
  • Tacrolimus-resistant SARS-CoV-2-specific T-cell products to prevent and treat severe COVID-19 in immunosuppressed patients
    Peter et al., Molecular Therapy (2022) 
    Products used: PepMix™ SARS-CoV-2 (NCAP), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 (VEMP)SARS-CoV-2 (VME1)SARS-CoV-2 (AP3A)SARS-CoV-2 (NS7A)SARS-CoV-2 (NS7B)SARS-CoV-2 (ORF9B)SARS-CoV-2 (ORF10)SARS-CoV-2 (Spike B.1.1.7 / Alpha)SARS-CoV-2 (Spike B.1.351 / Beta)SARS-CoV-2 (Spike B.1.617.2 / Delta)SARS-CoV-2 (Spike B.1.1.529 / Omicron)CMVA (pp65)
  • Evaluation of IL-1β and IL-6 expression following EBNA-1 and BRLF-1 peptide treatment in Epstein Barr virus-positive multiple sclerosis patients
    Kianfar et al., Intervirology (2022)
  • Performance comparison of a fow cytometry immunoassay for intracellular cytokine staining and the QuantiFERON® SARS-CoV-2test for detection and quantifcation of SARS-CoV-2-Spike-reactiveIFN-γ-producing T cells after COVID-19 vaccination
    Tormo et al., European Journal of Clinical Microbiology & Infectious Diseases (2022) - PMID: 35165804
    Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
  • SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variant
    Panikkar et al., Pathogens (2022) - PMID: 35157735
    Products used: PepMix™ SARS-CoV-2 (AP3A)SARS-CoV-2 (NCAP)SARS-CoV-2 (VME1)SARS-CoV-2 (Spike Glycoprotein)
  • Polyfunctional pathogen-specific CD4+ T cells reside in the lungs and tumors of NSCLC patients
    Oja et al., BioRxiv (2022)
    Products used: PepMix™ HRSVB (Fusion Glycoprotein F0) & HRSVB (MSG)
  • T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all prior infected and vaccinated individuals
    Vivek Naranbhai et al., MedRxiv (2022) - PMID: 35018386
    Products used:  PepMix™ SARS-CoV-2 (Spike Glycoprotein)SARS-CoV-2 (NCAP)SARS-CoV-2 (VME1)SARS-CoV-2 (VEMP)SARS-CoV-2 (AP3A)SARS-CoV-2 (Spike B.1.617.2 / Delta)
  • Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys
    Amarendra Pegu et al., Cell Report (2022) - PMID: 34986348
    Products used: PepMix™ HIV-1 (ENV) Ultra
  • Bystander CD4+ T cells infiltrate human tumors and are phenotypically distinct
    Shamin Li et al., OncoImmunology (2022) - PMID: n.a.
    Products used: PepMix™ CMVA (pp65)
  • Innate and adaptive immune defects associated with lower SARS-CoV-2 BNT162b2 mRNA vaccine response in elderly people
    Joana Vitallé et al., medRxiv (2022) - PMID: n.a.
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
  • Temporary hold of mycophenolate boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients
    Eva Schrezenmeier et al., MedRxiv (2022) 
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
  • Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents
    Nina Koerber et al., Nature Communications (2022)
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
  • Persistent T-Cell Reactivity in a Seronegative Patient after SARS-CoV-2 Infection and One Vaccination
    Nico Andreas et al., Vaccines (2022)
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
  • Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity
    Shinya Abe et al., Immunotherapy of Cancer (2022)
    Products used: PepMix™ HIV-1 (GAG) Ultra
  • Development of an effective immune response in adults with Down Syndrome 2 after SARS-CoV-2 vaccination
    Laura Esparcia-Pinedo et al., MedRxiv (2022) 
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 (VME1)SARS-CoV-2 (NCAP)SARS-CoV-2 (Nsp5)
  • Wnt activation promotes memory T cell polyfunctionality via epigenetic regulator PRMT1
    Bo-Yi Sung et al., Journal of Clinical Investigation (2022) - PMID: 35040433
    Products used: PepMix™ CMVA (pp65)
  • Clinical and Immunological Characteristics for BK Polyomavirus- associated Nephropathy after Kidney Transplantation
    Tanaya Siripoon et al., Research Square (2022)
    Products used: PepMix™ BKV (capsid protein VP1)BKV (large T antigen)
  • T cell response to intact SARS-CoV-2 includes coronavirus cross-reactive and variant-specific components
    Lichen Jing et al., MedRxiv et al., (2022)
    Products used: PepMix™ HCoV-OC43 (Spike Glycoprotein)
  • Persistently reduced humoral and cellular immune response following third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients
    Bajwa et al., MedRxiv (2022)
  • Antibody and T cell responses to SARS-CoV-2 mRNA vaccines during maintenance therapy for immune-mediated inflammatory diseases
    Dayam et al., MedRxiv (2022)
  • Infection or a third dose of mRNA vaccine elicit neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients
    Charmetant et al., Science Translational Medicine (2022) - PMID: 35103481
    Products used: PepMix™ SARS-CoV-2 (NCAP)SARS-CoV-2 (Spike Glycoprotein)SARS-CoV-2 (VME1)
  • Concordance of B and T cell responses to SARS-CoV-2 infection, irrespective of symptoms suggestive of COVID-19
    Österdahl et al., MedRxiv (2022) 
  • Differential localization and limited cytotoxic potential of duodenal CD8+ T cells
    Mvaya et al., JCI Insight (2022) - PMID: 35132966
    Products used: PepMix™ HIV-1 (POL)HIV-1 (GAG) & HIV-1 (NEF) 
  • Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice
    Lázaro-Frías et al., Vaccines (2022) 
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
  • mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron
    Gagne et al., BioRxiv (2022)
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
  • A Co-stimulatory CAR Improves TCR-based Cancer Immunotherapy
    Omer et al., Cancer Immunology Research (2022) - PMID: 35176142
    Products used: PepMix™ EBV (EBNA1), EBV (LMP1)EBV (LMP2)
  • Effectiveness and durability of the mRNA vaccine-induced SARSCoV-2-specific humoral and cellular immunity in severe asthma patients on biological therapy
    Prodrazil et al., MedRxiv (2022)
    Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
  • Impaired Anti-SARS-CoV-2 Humoral and Cellular Immune Response Induced by Pfizer-BioNTech BNT162b2 mRNA Vaccine in Solid Organ Transplanted Patients
    Monica Miele, American Journal of Transplantation (2021) - PMID: 34058052
  • CD8+ T Cells Specific for an Immunodominant SARS-CoV-2 Nucleocapsid Epitope Cross-React With Selective Seasonal Coronaviruses
    Katie E Lineburg, Immunity (2021) - PMID: 33945786
  • Prime hAd5 Spike plus Nucleocapsid Vaccination Induces Ten-Fold Increases in Mean T-Cell Responses in Phase 1 Subjects that are Sustained Against Spike Variants
    Pete Sieling, medRxiv (2021) - PMID: n.a.
  • Gene Transfer in Adeno-Associated Virus Seropositive Rhesus Macaques Following Rapamycin Treatment and Subcutaneous Delivery of AAV6, but Not Retargeted AAV6 Vectors
    Stone et al., Human Gene Therapy (2021) - PMID: 32998579
  • Preclinical Evaluation of a SARS-CoV-2 mRNA Vaccine PTX-COVID19-B
    Jun Liu, bioRxiv (2021) - PMID: n.a.
  • A Lymph Node-Targeted Amphiphile Vaccine Induces Potent Cellular and Humoral Immunity to SARS-CoV-2
    Martin P Steinbuck, Sci Adv. (2021) - PMID: 33446655
  • SARS-CoV-2 Spike Glycoprotein Vaccine Candidate NVX-CoV2373 Immunogenicity in Baboons and Protection in Mice
    Jing-Hui Tian, Nat Commun (2021) - PMID: 33446655
  • Safety and Immunogenicity of the SARS-CoV-2 BNT162b1 mRNA Vaccine in Younger and Older Chinese Adults: a Randomized, Placebo-Controlled, Double-Blind Phase 1 Study
    Jingxin Li, Nat Med. (2021) - PMID: 33888900
  • BNT162b Vaccines Protect Rhesus Macaques From SARS-CoV-2
    Annette B Vogel, Nature (2021) - PMID: 33524990
  • Older Adults Lack SARS CoV-2 Cross-Reactive T Lymphocytes Directed to Human Coronaviruses OC43 and NL63es
    Giulietta Saletti, Sci Rep. (2021) - PMID: 33293664
  • SARS-CoV-2 Variants of Concern Partially Escape Humoral but not T-Cell Responses in COVID-19 Convalescent Donors and Vaccinees
    Daryl Geers, Sci Immunol. (2021) - PMID: 34035118
  • COVID-19 Immune Signatures Reveal Stable Antiviral T Cell Function Despite Declining Humoral Responses
    Agnes Bonifacius, Immunity (2021) - PMID: 33567252
  • IL-33 Expression in Response to SARS-CoV-2 Correlates With Seropositivity in COVID-19 Convalescent Individuals
    Michal A Stanczak, Nat Commun. (2021) - PMID: 33837219
  • A Highly Specific Assay for the Detection of SARS-CoV-2-Reactive CD4 + and CD8 + T Cells in COVID-19 Patients
    Henning Zelba, J Immunol. (2021) - PMID: 33298615
  • SARS-CoV-2-Reactive T Cells in Healthy Donors and Patients With COVID-19
    Julian Braun, Nature (2021) - PMID: 32726801
  • Functional Characterization of CD4+ T Cell Receptors Crossreactive for SARS-CoV-2 and Endemic Coronaviruses
    Arbor G Dykema, J Clin Invest. (2021) - PMID: 33830946
  • Culture Media Optimization for Chinese Hamster Ovary Cell Growth and Expression of Recombinant Varicella-Zoster Virus Glycoprotein E
    Kwang Sung Kim, Cytotechnology (2021) - PMID: 33897103
  • SARS-CoV-2 Protein Subunit Vaccination of Mice and Rhesus Macaques Elicits Potent and Durable Neutralizing Antibody Responses
    Marco Mandolesi, Cell Reports Medicine (2021) - PMID: 33842900
  • SARS-CoV-2 mRNA Vaccine BNT162b2 Elicited a Robust Humoral and Cellular Response Against SARSCoV-2 Variants
    Daniele Lilleri, Research Square (2021) - PMID: n.a.
  • Children Develop Strong and Sustained Cross-Reactive Immune Responses Against Spike Protein Following SARS-CoV-2 Infection, With Enhanced Recognition of Variants of Concern
    Alexander C. Dowell, medRxiv (2021) - PMID: n.a.
  • Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2
    Krystle K.Q. Yu, JCI Insight (2021) - PMID: 33621211
  • Targeting SARS-CoV-2 Receptor-Binding Domain to Cells Expressing CD40 Improves Protection to Infection in Convalescent Macaques
    Romain Marlin, Nature Communications (2021) - PMID: n.a.
  • Characterization of Recombinant Gorilla Adenovirus HPV Therapeutic Vaccine PRGN-2009
    Samuel T. Pellom, JCI Insight (2021) - PMID: 33651712
  • Cytomegalovirus-Specific T-Cell Reconstitution Following Letermovir Prophylaxis after Hematopoietic Cell Transplantation
    Danniel Zamora, In Press, Journal Pre-proof (2021) - PMID: 33657225
  • Optimization of Zika DNA Vaccine by Delivery Systems
    Yun Ha Lee, Virology (2021) - PMID: 33780719
  • Human Cytomegalovirus and Epstein-Barr Virus Specific Immunity in Patients With Ulcerative Colitis
    Rachele Ciccocioppo, Clinical and Experimental Medicine (2021) - PMID: 33772380
  • Longitudinal Analysis of Human Memory T-Cell Response according to the Severity of Illness up to 8 Months after SARS-CoV-2 Infection
    Chang Kyung Kang, The Journal of Infectious Diseases (2021) - PMID: 33755725
  • Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection
    Jianmin Zuo, Nature (2021) - PMID: 33674800
  • SARS-CoV-2 Spike Protein Arrested In The Closed State Induces Potent Neutralizing Responses
    George W. Carnell, bioRxiv (2021) - PMID: n.a.
  • First Report Demonstrating The Safety And Immunogenicity Of The SARS-COV-2 BNT162b1 mRNA Vaccine In Younger And Older Chinese Adults: A Randomized, Placebo-Controlled, Observer-Blind Phase I Study
    Fengcai Zhu, Research Square (2021) - PMID: n.a.
  • Validation of an IFN-Gamma ELISpot Assay to Measure Cellular Immune Responses Against Viral Antigens in Non-Human Primates
    Fan Yang, Gene Ther. (2021) - PMID: 33432123
  • Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated With Belatacept
    Nathalie Chavator et al., Transplantation, (2021)
  • SARS-CoV-2 Specific Memory T Cell Epitopes Identified in COVID-19-Recovered Subjects
    Juan Zhao et al., Virus Res, (2021)
  • Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France
    Floriane Gallais et al., Emerg Infect Dis, (2021)
  • SARS-CoV2 Mutant-Specific T Cells and Neutralizing Antibodies After Vaccination and up to 1 Year After Infection
    Richardson, J.R. et al., ISAR Bioscience, (2021)
  • COVID-19 Subunit Vaccine with a Combination of TLR1/2 and TLR3 Agonists Induces Robust and Protective Immunity
    Soo-Kyung Jeong et al., Vaccines, (2021)
  • M2-Deficient Single-Replication Influenza Vaccine–Induced Immune Responses Associated With Protection Against Human Challenge With Highly Drifted H3N2 Influenza Strain
    Joseph Eiden et al., J Infect Dis, (2021)
  • Impairment of CD4+ T and Memory B Cell Responses but Normal Memory CD8+T-Cell Activation on Crohn’s Disease after COVID-19 Vaccination: A Twin Case
    Fabiana Gil-Melgaço et al., Viruses, (2021)
  • Weak Immunogenicity of SARS-CoV-2 Vaccine in Patients With Hematologic Malignancies
    Florent Malard et al., Blood Cancer J, (2021)
  • CD4+ T Cells of Prostate Cancer Patients Have Decreased Immune Responses to Antigens Derived From SARS-CoV-2 Spike
    Pavla Taborska et al., Front Immunol, (2021)
  • T Cell–Mediated Response to SARS-CoV-2 in Liver Transplant Recipients With Prior COVID-19
    Mario Fernández-Ruiz et al., Am J Transplant, (2021)
  • Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) Study: an Observational Cohort Study of SARS-CoV-2 Infection and Vaccination in Healthcare Workers
    Jackson, B.M. et al., BMC Infect Dis, (2021)
  • Cellular Immunity Predominates Over Humoral Immunity After Homologous and Heterologous mRNA and Vector-Based COVID-19 Vaccine Regimens in Solid Organ Transplant Recipients
    Tina Schmidt et al., Am J Translplant, (2021)
  • The Legacy of Maternal SARS-CoV-2 Infection on the Immunology of the Neonate
    Sarah Gee et al., Nat Immunol, (2021)
  • A Single-Cycle Influenza A Virus-Based SARS-CoV-2 Vaccine Elicits Potent Immune Responses in a Mouse Model
    Surapong Koonpaew et al., Vaccines, (2021)
  • Impact of Multiple Sclerosis Disease-Modifying Therapies on SARS-CoV-2 Vaccine-Induced Antibody and T Cell Immunity
    Sabatino, J.J. et al., MedRxiv, (2021)
  • Complete Protection of Nasal and Lung Airways Against SARS-CoV-2 Challenge by Antibody Plus Th1 Dominant N- and S-Specific T-Cell Responses to Subcutaneous Prime and Thermally-Stable Oral Boost Bivalent hAd5 Vaccination in an NHP Study
    Elizabeth Gabitzsch et al., BioRxiv, (2021)
  • Cytomegalovirus-Specific Immunity Recovers More Slowly after Cord Blood Transplantation Compared with Matched Sibling Donor Allogeneic Transplantation
    Bejanyan, J. et al., Transplant Cell Ther, (2021)
  • The Evaluation of Novel Oral Vaccines Based on Self-Amplifying RNA Lipid Nanparticles (saRNA LNPs), saRNA Transfected Lactobacillus Plantarum LNPs, and saRNA Transfected Lactobacillus Plantarum to Neutralize SARS-CoV-2 Variants Alpha and Delta
    Reza Keikha et al., Sci Rep, (2021)
  • Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge
    King R.G. et al., Vaccines, (2021)
  • T-Cell and Antibody Immunity After COVID-19 mRNA Vaccines in Healthy and Immunocompromised Subjects-An Exploratory Study
    Rakesh Sindhi et al., MedRxiv, (2021)
  • SARS-CoV-2-Specific Antibody and T Cell Response Kinetics According to Symptom Severity
    Ji Yeun Kim et al., Am J Trop Med Hyg, (2021)
  • Implementation of Adenovirus-Mediated Pulmonary Expression of Human ACE2 in HLA Transgenic Mice Enables Establishment of a COVID-19 Murine Model for Assessment of Immune Responses to SARS-CoV-2 Infection
    Theodor Chitlaru et al., Pathogens, (2021)
  • Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial
    Punnee Pitisuttihum et al., MedRxiv, (2021)
  • Protracted yet Coordinated Differentiation of Long-Lived SARS-CoV-2-Specific CD8+ T Cells During COVID-19 Convalescence
    Tongcui Ma et al., BioRxiv, (2021)
  • SARS-Cov-2 Spike Protein Fragment 674–685 Protects Mitochondria From Releasing Cytochrome c in Response to Apoptogenic Influence
    Olena Kalashnyk et al., Biochem Biophys Res Commun, (2021)
  • CD8+PD-L1+CXCR3+ Polyfunctional T Cell Abundances Are Associated With Survival in Critical SARS-CoV-2–Infected Patients
    Lucille Adam et al., JCI Insight, (2021)
  • Protective Antibodies Elicited by SARS-CoV-2 Spike Protein Vaccination are Boosted in the Lung After Challenge in Nonhuman Primates
    Joseph R. Francica et al., Sci Transl Med, (2021)
  • Profiling SARS-CoV-2 HLA-I Peptidome Reveals T Cell Epitopes From Out-of-Frame ORFs
    Shira Weingarten-Gabbay et al., Cell, (2021)
  • A Short Corticosteroid Course Reduces Symptoms and Immunological Alterations Underlying Long-COVID
    Alberto Utrero-Rico et al., Biomedicines, (2021)
  • COVID-19 Vaccine mRNA-1273 Elicits a Protective Immune Profile in Mice That is not Associated With Vaccine-Enhanced Disease Upon SARS-CoV-2 Challenge
    DiPiazza, A.T. et al., Immunity, (2021)
  • Polymeric and Lipid Nanoparticles for Delivery of Self-Amplifying RNA Vaccines
    Blakney, A.K. et al., J Control Release, (2021)
  • An Enveloped Virus-Like Particle Vaccine Expressing a Stabilized Prefusion form of the SARS-CoV-2 spike Protein Elicits Highly Potent Immunity
    Anne-Catherine Fluckiger et al., Vaccine, (2021)
  • Intranasal Plus Subcutaneous Prime Vaccination With a Dual Antigen COVID-19 Vaccine Elicits T-Cell and Antibody Responses in Mice
    Adrian Rice et al., Sci Rep, (2021)
  • Change in Symptoms and Immune Response in People with Post-Acute Sequelae of SARS-Cov-2 Infection (PASC) After SARS-Cov-2 Vaccination
    Daisy Massay et al., MedRxiv, (2021)
  • Evolution of SARS-CoV-2 Immune Responses in Nursing Home Residents Following Full Dose of the Comirnaty® COVID-19 Vaccine
    Giménez, E. et al., J Infect (2021)
  • Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera
    Vidal, S-J. et al., J Virol, (2021)
  • Application of Spectral Library Prediction for Parallel Reaction Monitoring of Viral Peptides
    Grossegesse, M. et al., Proteomics, (2021)
  • Preserved T-cell Response in anti-CD20 Treated Multiple Sclerosis Patients Following SARS-CoV-2 Vaccination
    Simon Faissner et al., Res Square, (2021)
  • Durable T cell responses contrast with faster antibody waning in BNT162b2-vaccinated elderly at 6 month
    Laurent Renia et al., Res Square, (2021)
  • SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses
    Joshua M. Carmen et al., Vaccines, (2021)
  • mRNA Vaccine Protects against Zika Virus
    Lex G. Medina-Magües et al., Vaccines, (2021)
  • A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates
    M. Gordon Joyce et al., Science Translational Medicine
  • SARS-CoV-2-Specific Cell-Mediated Immunity in Kidney Transplant Recipients Recovered From COVID-19
    Mario Fernández-Ruiz et al., Transplantation, (2021)
  • First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers
    Fenne L. Komdeur et al., Mol Ther, (2021)
  • SARS-CoV-2 Vaccination in Rituximab-Treated Patients: B Cells Promote Humoral Immune Responses in the Presence of T-Cell-Mediated Immunity
    Daniel Mrak et al., Ann Rheum Dis, (2021)
  • Comorbid Illnesses are Associated With Altered Adaptive Immune Responses to SARS-CoV-2
    Krystle Kq Yu et al., JCI Insight, (2021)
  • Longitudinal Analysis of Human Memory T-Cell Response According to the Severity of Illness up to 8 Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection
    Chang Kyung Kang et al., J Infect Dis, (2021)
  • Deconvoluting the T Cell Response to SARS-CoV-2: Specificity Versus Chance and Cognate Cross-Reactivity
    Alexander A. Lehmann et al., Front Immunology, (2021)
  • Identification of Conserved SARS-CoV-2 Spike Epitopes That Expand Public cTfh Clonotypes in Mild COVID-19 Patients
    Xiuyuan Lu et al., J Exp Med, (2021)
  • Cytomegalovirus Specific Polyfunctional T-Cell Responses Expressing CD107a Predict control of CMV Infection After Liver Transplantation
    Ângela Carvalho-Gomes et al., Cellular Immunology, (2021)
  • Off the Shelf Third Party Virus Specific T-Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplant Recipients
    Jeremy D. Rubinstein et al., Transplant Cell Ther, (2021)
  • Effectiveness of ChAdOx1 nCoV-19 Vaccine Against SARS-CoV-2 Infection During the Delta (B.1.617.2) Variant Surge in India: a Test-Negative, Case-Control Study and a Mechanistic Study of Post-Vaccination Immune Responses
    Ramachandran Thiruvengadam et al., Lancet Infect Dis, (2021)
  • Rituximab impairs B-cell response but not T-cell response to COVID-19 vaccine in auto-immune diseases
    Samuel Bitoun et al., Arthritis & Rheumatology, (2021)
  • Latent CMV Infection Is Associated With Lower Influenza Virus-Specific Memory T-Cell Frequencies, but Not With an Impaired T-Cell Response to Acute Influenza Virus Infection
    Sarah P.H. van den Berg et al., Front Immunology, (2021)
  • Rituximab impairs B-cell response but not T-cell response to COVID-19 vaccine in auto-immune diseases
    Samuel Bitoun et al., Arthritis & Rheumatology (2021) - PMID: 34962357
  • Latent CMV Infection Is Associated With Lower Influenza Virus-Specific Memory T-Cell Frequencies, but Not With an Impaired T-Cell Response to Acute Influenza Virus Infection
    Sara P H van den Berg et al., Front Immunology (2021) - PMID: 34025665
  • CMV-Specific Immunity Recovers Slowly after Cord Blood Compared with Matched Sibling Donor Allogeneic Transplantation
    N.Bejanyan, Transplantation and Cellular Therapy (2020) - PMID: n.a.
  • Human Cytomegalovirus-Encoded microRNAs Can Be Found in Saliva Samples from Renal Transplant Recipients
    Shelley Waters, Noncoding RNA. (2020) - PMID: 33353107
  • Persistent Cellular Immunity to SARS-CoV-2 Infection
    Gaëlle Breton, bioRxiv (2020) - PMID: 33330867
  • Adaptive Immune Responses to SARS-CoV-2 in Recovered Severe COVID-19 Patients
    Beatriz Olea, medRxiv (2020) - PMID: n.a.
  • 1IL-2 and IFN-γ are Biomarkers of SARS-CoV-2 Specific Cellular Response in Whole Blood Stimulation Assays
    Begoña Pérez-Cabezas, medRxiv (2020) - PMID: n.a.
  • BNT162b2 Induces SARS-CoV-2-Neutralising Antibodies and T Cells in Humans
    Ugur Sahin, medRxiv (2020) - PMID: n.a.
  • Deconvoluting the T Cell Response to SARS-CoV-2: Specificity Versus Chance- and Cognate Cross-Reactivity
    Alexander A. Lehmann, bioRxiv (2020) - PMID: n.a.
  • Guidelines For Analysis of Low-Frequency Antigen-Specific T Cell Results: Dye-Based Proliferation Assay vs 3H-Thymidine Incorporation
    Daniela Di Blasi, Journal of Immunological Methods (2020) - PMID: 33152332
  • Antigenic Competition in the Generation of Multi-Virus-Specific Cell Lines for Immunotherapy of Human Cytomegalovirus, Polyomavirus BK, Epstein-Barr Virus and Adenovirus Infection in Haematopoietic Stem Cell Transplant Recipients
    Kateřina Roubalová, Immunol Lett. (2020) - PMID: 33031870
  • Convalescent Plasma Therapy for B-Cell Depleted Patients With Protracted COVID-19 Disease
    Thomas Hueso, Blood (2020) - PMID: 32959052
  • mRNA Based SARS-CoV-2 Vaccine Candidate CVnCoV Induces High Levels of Virus Neutralizing Antibodies and Mediates Protection in Rodents
    Susanne Rauch, bioRxiv (2020) - PMID: n.a.
  • Functional Immune Monitoring of BK Virus And Donor‐Specific T‐cell Effector Immune Responses to Guide Treatment Decision‐Making After Kidney Transplantation; an Illustrative Case Report And Literature Review
    Marta Lepore, Transplant Infectious Disease (2020) - PMID: 33070461
  • Divergent SARS‐CoV‐2‐Specific T and B Cell Responses in Severe but Not Mild COVID‐19 Patients
    Anna E. Oja, European Journal of Immunology (2020) - PMID: 33073359
  • Characteristicsof Rapamycin-Treated T Cell Products for Advanced Adoptive T Cell Therapy and Evaluation of Clinical Feasibility
    Leila Amini, Dissertation (2020) - PMID: n.a.
  • Intrafamilial Exposure to SARS-CoV-2 Induces Cellular Immune Response without Seroconversion
    Gallais F., Emerg Infect Dis (2020) - PMID: n.a.
  • T Cell and Antibody Responses to SARS-CoV-2: Experience From a French Transplantation and Hemodialysis Center During the COVID-19 Pandemic
    Candon S., Am J Transplant (2020) - PMID: n.a.
  • Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
    Evan J. Anderson, New England Journal of Medicine (2020) - PMID: 32991794
  • Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques
    Mercado, Nature (2020) - PMID: 32731257
  • Evaluation of the mRNA-1273 Vaccine Against SARS-CoV-2 in Nonhuman Primates
    Corbett, N Engl J Med (2020) - PMID: 32722908
  • Divergent SARS-CoV-2-Specific T and B Cell Responses in Severe but not Mild COVID-19
    Oja, bioRxiv (2020) - PMID: n.a.
  • Self-Amplifying RNA SARS-CoV-2 Lipid Nanoparticle Vaccine Candidate Induces High Neutralizing Antibody Titers in Mice
    McKay, Nature (2020) - PMID: 32647131
  • Generation of SARS-CoV-2 S1 Spike Glycoprotein Putative Antigenic Epitopes in Vitro by Intracellular Aminopeptidases
    Stamatakis, bioRxiv (2020) - PMID: n.a.
  • SARS-CoV-2-Specific T Cells Exhibit Unique Features Characterized by Robust Helper Function, Lack of Terminal Differentiation, and High Proliferative Potential
    Neidleman, bioRxiv (2020) - PMID: 32577663
  • A Longitudinal Study of Immune Cells in Severe COVID-19 Patients
    Payen, medRXiv (2020) - PMID: n.a.
  • SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness
    Corbett, bioRxiv (2020) - PMID: 32577634
  • Presence of SARS-CoV-2 Reactive T Cells in COVID-19 Patients and Healthy Donors
    Braun, Nature (2020) - PMID: 32726801
  • SARS‐CoV‐2‐Reactive Interferon‐γ‐Producing CD8+ T Cells in Patients Hospitalized with Coronavirus Disease 2019
    Estela Giménez, Journal of Medical Virology (2020) - PMID: 32579268
  • Evaluation of T-Activated Proteins as Recall Antigens to Monitor Epstein–Barr Virus and Human Cytomegalovirus-Specific T Cells in a Clinical Trial Setting
    Nina Körber, Journal of Translational Medicine (2020) - PMID: 32552697
  • Modified Alphavirus-Vesiculovirus Hybrid VaccineVectors for Homologous Prime-Boost Immunotherapyof Chronic Hepatitis B
    Carolina Chiale, Vaccines (2020) - PMID: 32517032
  • Duration of Cellular and Humoral Responses After Quadrivalent Human Papillomavirus Vaccination in Healthy Female Adultswith or Without Prior Type 16 and/or 18 Exposure
    Lilin Lai, Vaccines (2020) - PMID: n.a.
  • A SARS-CoV-2 mRNA Vaccine — Preliminary Report
    Lisa A Jackson, N Engl J Med (2020) - PMID: 32663912
  • HBV‐Specific CD8 T Cells Present Higher TNFα Expression But Lower Cytotoxicity in Hepatocellular Carcinoma
    Ludong Zhao, Clinical & Experimental Immunology (2020) - PMID: 32474905
  • Safety and Immunogenicity of a Zika Purified Inactivated Virus Vaccine Given Via Standard, Accelerated, or Shortened Schedules: a Single-Centre, Double-Blind, Sequential-Group, Randomised, Placebo-Controlled, Phase 1 Trial
    Kathryn E Stephenson, The Lancet Infectious Diseases (2020) - PMID: n.a.
  • Assessing Anti-HCMV Cell Mediated Immune Responses in Transplant Recipients and Healthy Controls Using a Novel Functional Assay
    Charlotte J. Houldcroft, Cell-Mediated Immunity to HCMV (2020) - PMID: n.a.
  • Evaluation of Glycoprotein E Subunit And Live Attenuatedvaricella‐Zoster Virus Vaccines Formulated With Asingle‐Strand RNA‐Based Adjuvant
    Su Jeen Lee, Immunity, Inflammation and Disease (2020) - PMID: 32167678
  • Women Who Received Varicella Vaccine Versus Natural Infection Have Different Long-Term T Cell Immunity but Similar Antibody Levels
    Ellen Tourtelot, Vaccine (2020) - PMID: 31959424
  • TGF‐β Promotes The Function Of HIV‐Specific CXCR5+CD8 T Cells
    Hong-Ge Yang, Microbiology and Immunology (2020) - PMID: 32221997
  • Persistent Expansion And Th1-Like Skewing of HIV-Specific Circulating T Follicular Helper Cells During Antiretroviral Therapy
    Julia Niessl Wu, EBioMedicine (2020) - PMID: 32268275
  • Preserved Specific Anti-Viral T-Cell Response But Associated With Decreased Lupus Activity In SLE Patients With Cytomegalovirus Infection
    Chien-Sheng Wu, British Society for Rheumatology (2020) - PMID: 32306043
  • A Chimeric Yellow Fever-Zika Virus Vaccinecandidate Fully Protects Against Yellow Fever Virusinfection in Mice
    Dieudonné Buh Kum, Emerging Microbes & Infections (2020) - PMID: 32116148
  • Efficacy, Immunogenicity, and Safety of an Oral Influenza Vaccine: a Placebo-Controlled And Active-Controlled Phase 2 Human Challenge Study
    David Liebowitz, The Lancet Infectious Diseases (2020) - PMID: 31978354
  • Immunogenicity of Novel mRNA COVID-19 Vaccine MRT5500 in Mice and 2 Non-Human Primates
    Kirill V. Kalnin, Cancer Discovery (2019) - PMID: n.a.
  • Tracking Dye‐Independent Approach to Identify and Isolate In Vitro Expanded T Cells
    George Elias, Journal of Quantitative Cell Science (2019) - PMID: 31356002
  • Adenovirus Vector-Based Vaccines Confer Maternal-Fetal Protection against Zika Virus Challenge in Pregnant IFN-αβR−/− Mice
    Rafael A.Larocca, Clinical and Translational Report (2019) - PMID: 31668877
  • Tumor-Infiltrating B Cells Affect the Progression of Oropharyngeal Squamous Cell Carcinoma Via Cell-To-Cell Interactions With CD8+ T Cells
    Kamila Hladikova, Journal for ImmunoTherapy of Cancer (2019) - PMID: 31623665
  • PD-1 Blockade and TLR7 Activationlack Therapeutic Benefit in Chronic SIV-Infected Macaqueson Antiretroviral Therapy
    Elena Bekerman, Antimicrob. Agents Chemother. (2019) - PMID: 31501143
  • Deciphering Effects of Uncontrolled Cytomegalovirus Replication on Immune Responses in Cytomegalovirus DNA-Positive Renal Transplant Recipients
    Nandini Makwana, Viral Immunology (2019) - PMID: 31536468
  • Generation of HPV-Specific T-Cells
    Carlos A. Ramos, United States Patent Application 20190224302 (2019) - PMID: n.a.
  • A Vaccine Based on Recombinant Modified Vaccinia Ankara Containing the Nucleoprotein from Lassa Virus Protects Against Disease Progression in a Guinea Pig Model
    E.M.Kennedy, Vaccine (2019) - PMID: 31331770
  • A Novel Simplified Method of Generating Cytomegalovirus-Specific Cytokine-Induced Killer Cells of High Specificity and Superior Potency with GMP Compliance
    Yen Hoon Luah, Clinical Immunology (2019) - PMID: 31229666
  • Generation of Zika Virus–Specific T Cells from Seropositive and Virus-Naïve Donors for Potential Use as an Autologous or “Off-the-Shelf” Immunotherapeutic
    Ryo Hanajiri, Cytotherapy (2019) - PMID: n.a.
  • HBeAg Seroconversion is Associated with a More Effective PD-L1 Blockade During Chronic Hepatitis B Infection
    Sara Ferrando-Martinez, JHEP Reports (2019) - PMID: n.a.
  • Enhancement of Immune Responses by Guanosine-Based Particles in DNA Plasmid Formulations against Infectious Diseases
    Saritza Santos, Journal of Immunology Research (2019) - PMID: n.a.
  • Prospective Assessment of CMV Immunity in High-Risk Donor Seropositive (D+) Recipient Seronegative (R-) Liver Transplant Recipients Receiving Either Preemptive Therapy or Prophylaxis
    Ajit P Limaye ,The Journal of Infectious Diseases (2019) - PMID: n.a.
  • Phenotypic and Functional Differences Between HHV-6 and HCMV Specific T-Cells
    Solène Fastenackels , Journal of Virology (2019) - PMID: 30996090
  • Evaluation of EBV- and HCMV-Specific T Cell Responses in Systemic Lupus Erythematosus (SLE) Patients Using a Normalized Enzyme-Linked Immunospot (ELISPOT) Assay
    Irene Cassaniti , PLoS Pathogens (2019) - PMID: n.a.
  • T-Cell Responses Targeting HIV Nef Uniquely Correlate With Infected Cell Frequencies After Long-Term Antiretroviral Therapy
    Allison S. Thomas , PLoS Pathogens (2019) - PMID: 28931091
  • Measurement of CD8.sup.+ and CD4.sup.+ T Cell Frequencies Specific for EBV LMP1 and LMP2a Using mRNA-Transfected DCs
    Dae-Hee Sohn , PLoS ONE (2019) - PMID: 26023769
  • Efficient Induction of Cell-Mediated Immunity to Varicella-Zoster Virus Glycoprotein E Co-Lyophilized with a Cationic Liposome-Based Adjuvant in Mice
    Seo Ri Wui , Vaccine (2019) - PMID: 30827737
  • Penalized Supervised Star Plots: Example Application in Influenza-Specific CD4+ T Cells
    Tyson H. Holmes , Viral Immunology (2019) - PMID: 30698511
  • Antigen-Specific TCR Signatures of Cytomegalovirus Infection
    Alina Huth , The Journal of Immunology (2018) - PMID: 30587531
  • Developmental Induction of Human T-cell Responses Against Candida Albicans and Aspergillus Fumigatus
    Katrin Vogel , Scientific Reportsvolume (2018) - PMID: 30442915
  • Activation of Resident Memory T Cells for Cancer Immunotherapy
    Masopust Jr , United States Patent Application 20180325952 (2018) - PMID: n.a.
  • Epstein-Barr Virus (EBV)-derived BARF1 Encodes CD4-and CD8-restricted Epitopes as Targets for T-cell Immunotherapy
    M Kalra , Cytotherapy (2018) - PMID: 30396848
  • Generating HPV Antigen-specific Cells from a Native T Cell Population
    CM Bollard , US Patent App. 15/771,648, 2018 (2018) - PMID: n.a.
  • Method For Preparing Genetically-Modified T Cells Which Express Chimeric Antigen Receptor
    Nishio , United States Patent Application 20180289742 (2018) - PMID: n.a.
  • PI Highlight
    LL Kelley , PACT Newsletter (2018) - PMID: n.a.
  • Replication Deficient Human Adenovirus Vector Serotype 19a/64: Immunogenicity in Mice and Female Cynomolgus Macaques
    Ragonnaud et al., Vaccine (2018) - PMID: 30190120
  • Establishment and Operation of a Third Party Virus-Specific T-Cell Bank Within an Allogeneic Stem Cell Transplant Program
    Withers et al., Biology of Blood and Marrow Transplantation (2018) - PMID: 30172015
  • Humoral and Cellular Immunity to RSV in Infants, Children and Adults
    Green et al., Vaccine (2018) - PMID: 30177258
  • Altered CD4+ T‐Cell Immunity in Nurses Occupationally Exposed to Viral Pathogens
    Elias et al., Clin Exp Immunol (2018) - PMID: 30076783
  • Dynamics of Virus‐Specific T Cell Immunity in Pediatric Liver Transplant Recipients
    Arasaratnam et al., American Journal of Transplantation (2018) - PMID: 29900673
  • Pepmixes To Generate Multiviral Ctls With Broad Specificity
    Leen et al., US Patent App. 15/905,176, (2018) - PMID: n.a.
  • Deleterious Effect of Steroids on Cytomegalovirus Infection Rate after Allogeneic Stem Cell Transplantation Depends on Pretransplant Cytomegalovirus Serostatus of Donors and Recipients
    Suárez-Lledó et al., Biology of Blood and Marrow Transplantation (2018) - PMID: 29753162
  • Antiviral T Cells for Adenovirus in the Pretransplant Period: A Bridge Therapy for Severe Combined Immunodeficiency
    Miller et al., Biology of Blood and Marrow Transplantation (2018) - PMID: 29753156
  • Employment of the Human Thymus as an Alternative Source of Regulatory T-Cells to Develop an Immunotherapy to Prevent Rejection in Transplanted Children
    Bernaldo de Quirós et al., Cytotherapy (2018) - PMID: n.a.
  • Production of Quadrivalent Virus-Specific T Cells Utilizing Peptide Stimulation
    A. Damen et al., Cytotherapy (2018) - PMID: n.a.
  • An Antigen-Free, Plasmacytoid Dendritic Cell–Targeting Immunotherapy To Bolster Memory CD8+ T Cells in Nonhuman Primates
    Masuta et al., J Immunol. (2018) - PMID: 29431693
  • Multi-Antigenic Human Cytomegalovirus mRNA Vaccines that Elicit Potent Humoral and Cell-Mediated Immunity
    John et al., Sci Rep. (2018) - PMID: 29456015
  • Cytomegalovirus-Specific T-Cells Are Associated with Immune Senescence, But Not With Systemic Inflammation, in People Living with HIV
    Ballegaard et al., Sci Rep. (2018) - PMID: 29491459
  • Toward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood
    Corrales et al., Mol Ther Methods Clin Dev. (2017) - PMID: 28480300
  • IL28B Genetic Variation and Cytomegalovirus-Specific T-cell Immunity in Allogeneic Stem Cell Transplant Recipients.
    Corrales et al., Journal of Medical Virology (2015) - PMID: 27591738
  • Mycobacteria-Specific Cytokine Responses Detect TB Infection and Distinguish Latent from Active TB
    Tebruegge et al., Am J Respir Crit Care Med. (2015) - PMID: 26030187
  • Method for Preparing Antigen-Specific Cytotoxic T-Cells by Using Activated B-Cells and use Thereof
    Kang et al., United States Patent Application 20180023054 (2018) - PMID: n.a.
  • Production of Trivalent Antigen-Specific T Cells Utilizing Viral Peptide Stimulation
    Heyenbruch et al., Biology of Blood and Marrow Transplantation (2018) - PMID: n.a.
  • Differential Expression of CD8+ T Cell Cytotoxic Effector Molecules in Blood and Gastrointestinal Mucosa in HIV-1 Infection
    Kiniry et al., The Journal of Immunology (2018) - PMID: 29352005
  • "Cytomegalovirus (CMV) Immune Monitoring with ELISPOT and QuantiFERON-CMV Assay in Seropositive Kidney Transplant Recipients"
    Lee et al., Plos One (2017) - PMID: 29232714
  • Asian Elephant T Cell Responses to Elephant Endotheliotropic Herpesvirus (EEHV)
    Fuery et al., Journal of Virology (2017) - PMID: 29263271
  • Follistatin-Like Protein-1 Upregulates Dendritic Cell-Based Immunity in Patients with Nasopharyngeal Carcinoma
    Wang Hong et al., Journal of Interferon & Cytokine Research (2017) - PMID: 29135371
  • Methods of Cell Culture for Adoptive Cell Therapy
    Vera et al., US Patent 20,170,267,973, 2017 (2017) - PMID: n.a.
  • The Effect of Genetic Variants Affecting NK Cell Function on Cardiovascular Health and the Burden on CMV
    Waters et al., Hum Immunol. (2017) - PMID: 28987961
  • Protein Structure Shapes Immunodominance in the CD4 T cell Response to Yellow Fever Vaccination
    Koblischke et al., Sci Rep. (2017) - PMID: 28827760
  • Immunologic Profiling of Human Metapneumovirus (hMPV) Towards the Development of a Targeted Immunotherapy
    Tzannou et al., The Journal of Infectious Diseases (2017) - PMID: n.a
  • Safety and Immunogenicity of a mRNA Rabies Vaccine in Healthy Adults: an Open-label, Non-randomised, Prospective, First-in-human Phase 1 Clinical Trial
    Alberer et al., Lancet. (2017) - PMID: 28754494
  • Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells
    Sung et al., EBioMedicine (2017) - PMID: 28803740
  • CpG Oligonucleotides Increase HBV-Specific Cytokine Responses in Whole Blood and Enhance Cytokine Release Assay Sensitivity
    Dammermann et al., J Virol Methods (2017) - PMID: 28739303
  • Elucidating CD8+ T-Cell Responses in the Rectal Mucosa During HIV Infection
    Kiniry et al., ProQuest (2017) - PMID: n.a.
  • Vaccination with a Codon-Optimized A27L-Containing Plasmid Decreases Virus Replication and Dissemination After Vaccinia Virus Challenge
    Martínez et al., Vaccine (2017) - PMID: 28629922
  • Pre-Transplant Immune Factors May be Associated with BK Polyomavirus Reactivation in Kidney Transplant Recipients
    DeWolfe et al., Plos one (2017) - PMID: 28562595
  • Decitabine Treatment Sensitizes Tumor Cells to T-Cell-Mediated Cytotoxicity in Patients with Myelodysplastic Syndromes
    Zheng Zhang et al., Am J Transl Res (2017) - PMID: 28337274
  • An Early Immediate Early Protein IE-1–Specific T-Cell Polyfunctionality Is Associated With a Better Control of Cytomegalovirus Reactivation in Kidney Transplantation
    Dekeyser et al., Kidney International Reports (2017) - PMID: n.a.
  • Development of a Replication-Deficient Adenoviral Vector-Based Vaccine Candidate for the Interception of HPV16- and HPV18-Induced Infections and Disease
    Khan et al., International Jounal of Cancer (2017) - PMID: 28263390
  • Breadth of T Cell Responses after Immunization with Adenovirus Vectors Encoding Ancestral Antigens or Polyvalent Papillomavirus Antigens
    Ragonnaud et al., Scandinavian Journal of Immunology (2017) - PMID: 28109028
  • Primary Cytomegalovirus Infection in Seronegative Kidney Transplant Patients Is Associated with Protracted Cold Ischemic Time of Seropositive Donor Organs
    Schlott et al., Plos One (2017) - PMID: 28129395
  • Perturbed CD8+ T Cell TIGIT/CD226/PVR Axis Despite Early Initiation of Antiretroviral Treatment in HIV Infected Individuals
    Tauriainen et al., Scientific Reports (2017) - PMID: 28084312
  • Development of Novel Replication-defective Lymphocytic Choriomeningitis Virus Vectors Expressing SIV Antigens
    MacMaster et al., Vaccine (2016) - PMID: 27899229
  • T Cells Infiltrating Diseased Liver Express Ligands for the NKG2D Stress Surveillance System
    Huang et al., Journal of Immunology (2016) - PMID: 28031333
  • Polynucleotides For Treating Oncogenic Viral Polypeptide Positive Tumors
    Lee et al., US Patent 20,160,376,324 (2016) - PMID: n.a.
  • Therapeutic Vaccine Targeting Epstein-Barr Virus Latent Protein, LMP1, Suppresses LMP1-Expressing Tumor Growth and Metastasis in Vivo
    Lin et al., BMC Cancer (2016) - PMID: 28056887
  • Immune Monitoring to Predict and Prevent Infection
    Palmer et al., US Patent 20,160,377,602, 2016 (2016) - PMID: na.
  • Predominance of Weakly Cytotoxic, T-betLowEomesNeg CD8+ T-Cells in Human Gastrointestinal Mucosa: Implications for HIV Infection.
    Kiniry et al., Mucosal Immunology (2016) - PMID: 27827375
  • Expression of DAI by an Oncolytic Vaccinia Virus Boosts the Immunogenicity of the Virus and Enhances Antitumor Immunity
    Hirvinen et al., Molecular Therapy (2016) - PMID: 27626058
  • αβ T Cell Receptor Germline CDR Regions Moderate Contact with MHC Ligands and Regulate Peptide Cross-Reactivity
    Attaf et al., Scientific Reports (2016) - PMID: 27775030
  • Mapping the Sequence Space of ZIKA and Related Viruses: High-Content Peptide Libraries for Immune Monitoring
    von Hoegen et al., (2016) - PMID: n.a.
  • The Challenge of Complexity: Peptide Tools for the Development of Immunotherapies
    Schnatbaum et al., (2016) - PMID: n.a.
  • Circulating Functional T Cells Specific to HHV6 Antigens in Individuals With Chromosomally Integrated HHV-6 (ciHHV6)
    Barozzi et al., Clinical Microbiology and Infection (2016) - PMID: 27404369
  • Human Papillomavirus 16 (HPV16) and HPV52 E6-Specific Immunity in HIV-Infected Adults on Combination Antiretroviral Therapy
    Leng et al., HIV Medicine (2016) - PMID: 27649852
  • Immune Responses Elicited by the GEN-003 Candidate HSV-2 Therapeutic Vaccine in a Randomized Controlled Dose-Ranging Phase 1/2a Trial
    Flechtner et al., Vaccine (2016) - PMID: 27642130
  • Functional Diversity of CMV-Specific T-Cells is Maintained in Older People and Significantly Associated with Protein Specificity and Response Size
    Bajwa et al., The Journal of Infetious Diseases (2016) - PMID: 27521364
  • Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge
    Magini et al., PloS one (2016) - PMID: 27525409
  • Increased Frequency of BK Virus-Specific Polyfunctional CD8+ T Cells Predict Successful Control of BK Viremia After Kidney Transplantation
    Schaenman et al., Transplantation (2016) - PMID: 27391197
  • Protective Efficacy of Multiple Vaccine Platforms Against Zika Virus Challenge in Rhesus Monkeys
    Abbink et al., Science (2016) - PMID: 27492477
  • Distinct Metabolic Requirements of Exhausted and Functional Virus-Specific CD8 T Cells in the Same Host
    Schurich et al., Cell reports (2016) - PMID: 27452473
  • Complementary Effects of IL-15 and IFN-α Induce Immunity in HBV Transgenic Mice
    Di Scala et al., Journal of virology (2016) - PMID: 27440883
  • Composition and Dynamics of the Uterine NK Cell KIR Repertoire in Menstrual Blood
    Ivarsson et al., Mucosal Immunol. (2016) - PMID: 27271316
  • Validation of an IFNγ/IL2 FluoroSpot Assay for Clinical Trial Monitoring
    Körber et al., J Transl Med. (2016) - PMID: 27297580
  • A Single Exercise Bout Enhances the Manufacture of Viral-Specific T-cells from Healthy Donors: Implications for Allogeneic Adoptive Transfer Immunotherapy
    Spielmann et al., Sci Rep (2016) - PMID: 27181409
  • Cellular Interferon Gamma and Granzyme B Responses to Cytomegalovirus-pp65 and Influenza N1 Are Positively Associated in Elderly
    Theeten et al., Viral Immunology (2016) - PMID: 27002465
  • Reconstitution of Cytomegalovirus-Specific T-Cell Response in Allogeneic Hematopoietic Stem Cell Recipients: the Contribution of Six Frequently Recognized, Virus-Encoded ORFs
    Nemeckova et al., Transpl Infect Dis. (2016) - PMID: 27061389
  • The VZV/IE63-Specific T Cell Response Prevents Herpes Zoster in Fingolimod-Treated Patients
    Mathias et al., Neurology (2016) - PMID: n.a.
  • Cytotoxic Polyfunctionality Maturation of Cytomegalovirus-pp65-specific CD4+ and CD8+ T-cell Responses in Older Adults Positively Correlates with Response Size
    Chiu et al., Sci Rep. (2016) - PMID: 26778409
  • Restoring Tissue-Like Functionality in Circulating CD8 T-Cells: Mechanistic Studies and Application in Immunomonitoring of Cancer Patients
    Wegner et al., Thesis for a doctoral degree at the Graduate School of Life Sciences, University Würzburg, Germany (2016) - PMID: n.a.
  • In Vitro Studies of the Impact of Maribavir on CMV-Specific Cellular Immune Responses
    Stachel et al., J Clin Virol. (2015) - PMID: 26780109
  • Generation of Broadly-Specific, Virus-Immune Cells Targeting Multiple HIV Antigens For Prenventive and Therapeutic Use
    Bollard et al., US Patent 20,150,359,876 (2015) - PMID: n.a.
  • Recombinant Particle Based Vaccines Against Human Cytomegalovirus Infection
    Wellnitz et al., US Patent 20,150,359,879 (2015) - PMID: n.a.
  • Induction Of Broad-Based Immunity and Protective Efficacy by Self-Amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin
    Brazzoli et al., Journal of Virology (2015) - PMID: 26468547
  • Functionally Active HIV-Specific T Cells that Target gag and nef Can Be Expanded from Virus-Naive Donors and Target a Range of Viral Epitopes: Implications for a Cure Strategy after Allogeneic HSCT
    Patel et al., Biology of Blood and Marrow Transplantation (2015) - PMID: n.a.
  • Characteristics of Immune Memory 10–15 years After Primary Hepatitis B Vaccination
    Hummel et al., Vaccine (2015) - PMID: n.a.
  • IL-12–Dependent Cytomegalovirus-Specific CD4+ T Cell Proliferation, T-bet Induction, and Effector Multifunction during Primary Infection Are Key Determinants for Early Immune Control
    Popescu et al., J Immunol. (2015) - PMID: 26663780
  • Safety of Human Immunisation With a Live-attenuated Mycobacterium Tuberculosis Vaccine: a Randomised, Double-blind, Controlled Phase I Trial
    Spertini et al., The Lancet Respiratory Medicine (2015) - PMID: n.a
  • Luciferase mRNA Transfection of Antigen Presenting Cells Permits Sensitive Non-radioactive Measurement of Cellular and Humoral Cytotoxicity
    Omokoko et al., Journal of Immunology Research (2015) - PMID: n.a.
  • A Novel Lipid Nanoparticle Adjuvant Significantly Enhances B Cell and T Cell Responses to Sub-unit Vaccine Antigens
    Swaminathan et al., Vaccine (2015) - PMID: 26555351
  • Peptide Libraries for the Comprehensive Coverage of the Tumor Mutanome for Immune Monitoring and Immuno Therapy
    von Hoegen et al., Journal for ImmunoTherapy of Cancer (2015)- PMID: n.a.
  • Prognostic Impact of Circulating Her-2-reactive T-cells Producing Pro- and/or anti-inflammatory Cytokines in Elderly Breast Cancer Patients
    Bailur et al., J Immunother Cancer. (2015) - PMID: 26500775
  • Targeting of Nucleoprotein to Chemokine Receptors by DNA Vaccination Results in Increased CD8+-mediated Cross Protection Against Influenza
    Baranowska et al., Vaccine (2015) - PMID: 26387432
  • An Immunoinformatic Approach for Identification of Trypanosoma cruzi HLA-A2-Restricted CD8+ T cell Epitopes
    Eickhoff et al., Hum Vaccin Immunother. (2015) - PMID: 26107442
  • Innate Immune Activity Correlates with CD4 T Cell-associated HIV-1 DNA Decline During Latency-Reversing Treatment with Panobinostat
    Olesen et al., Journal of Virology (2015) - PMID: 26223643
  • Chimpanzee Adenovirus– and MVA-Vectored Respiratory Syncytial Virus Vaccine is Safe and Immunogenic in Adults
    Green et al., Science Translational Medicine. (2015) - PMID: n.a
  • Efficacy of a Virus-Vectored Vaccine Against Human and Bovine Respiratory Syncytial Virus Infections
    Taylor et al., Science Translational Medicine. (2015) - PMID: n.a
  • Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation and Association With Occurrence and Outcome of Invasive Aspergillosis
    Stuehler et al., The Journal of Infectious Disease. (2015) - PMID: 25748323
  • CD4+CD28null T Lymphocytes Resemble CD8+CD28null T Lymphocytes in Their Responses to IL-15 and IL-21 in HIV-infected Patients
    Echeverría et al., J. Leukoc. Biol. (2015) - PMID: 26034206
  • Epstein-Barr Virus Reactivation Does Not Impact Total T-Cell Reconstitution But Is Associated With Decreased Functional T Cells after Stem Cell Transplantation
    Pietersma et al., J Clin Cell Immunol (2015) - PMID: n.a
  • T Cells Specific for Different Latent and Lytic Viral Proteins Efficiently Control Epstein-Barr Virus–Transformed B Cells
    Nowakowska et al., Cytotherapy (2015) - PMID: 26276009
  • Methods of Cell Culture for Adoptive Cell Therapy
    Vera et al., US Patent 20,150,175,966, 2015 - PMID: n.a
  • High-Density Preculture of PBMCs Restores Defective Sensitivity of Circulating CD8 T Cells to Virus- and Tumor-derived Antigens
    Wegner et al., Blood (2015) - PMID: 26024876
  • Metabolic Regulation of Hepatitis B Immunopathology by Myeloid-derived Suppressor Cells
    Pallett et al., Nature Medicine (2015) - PMID: 25962123
  • ABO‐Desensitization Affects Cellular Immunity and Infection Control after Renal Transplantation
    Schachtner et al., Transplant International (2015) - PMID: 26033637
  • The Tuberculosis Vaccine H4: IC31 is Safe and Induces a Persistent Polyfunctional CD4 T cell Response in South African Adults: A Randomized Controlled Trial
    Geldenhuys et al., Vaccine (2015) - PMID: 26048780
  • Priming with a Simplified Intradermal HIV-1 DNA Vaccine Regimen followed by Boosting with Recombinant HIV-1 MVA Vaccine Is Safe and Immunogenic: A Phase Iia Randomized Clinical Trial
    Munseri et al., PloSOne (2015) - PMID: 25875843
  • Comparing Humoral and Cellular Immune Response Against HBV Vaccine in Kidney Transplant Patients
    Friedrich et al., Am J Transplant. (2015) - PMID: 26137874
  • Guidelines For the Automated Evaluation of Elispot Assays
    Janetzki et al., Nature Protocols (2015) - PMID: 26110715
  • Peripheral Blood–Derived Virus-Specific Memory Stem T Cells Mature to Functional Effector Memory Subsets with Self-Renewal Potency
    Schmueck-Henneresse, The Journal of Immunology (2015) - PMID: 25917088
  • A Comparative Phase 1 Clinical Trial to Identify Anti-infective Mechanisms of Vitamin D in People With HIV Infection
    Lachmann et al., AIDS (2015) - PMID: 25870995
  • HCV-Specific Lymphocyte Responses in Individuals with Positive Anti-HCV but Negative HCV-RNA
    Sili et al., Journal of Clinical Virology (2015) - PMID: n.a.
  • Safety and Immunogenicity of a Modified Vaccinia Ankara-based HIV-1 Vaccine (MVA-B) in HIV-1-Infected Patients Alone or in Combination with a Drug to Reactivate latent HIV-1
    Mothe et al., J Antimicrob Chemother. (2015) - PMID: 25724985
  • A Single Bout of Dynamic Exercise by Healthy Adults Enhances the Generation of Monocyte-Derived-Dendritic Cells
    LaVoy et al., Cellular Immunology (2015) - PMID: n.a.
  • Discordant Humoral and Cellular Immune Responses to Cytomegalovirus (CMV) in Glioblastoma Patients Whose Tumors are Positive for CMV
    Rahbar et al., OncoImmunology (2015) - PMID: n.a.
  • Early Transduction Produces Highly Functional Chimeric Antigen Receptor-modified Virus-specific T-cells with Central Memory Markers: a Production Assistant for Cell Therapy (PACT) Translational Application
    Sun et al., J Immunother Cancer. (2015) - PMID: 25734008
  • Role of Naïve-Derived T Memory Stem Cells in T Cell Reconstitution Following Allogeneic Transplantation
    Roberto et al., Blood. (2015) - PMID: 25742699
  • Multispecific Aspergillus T Cells Selected by CD137 or CD154 Induce Protective Immune Responses Against the Most Relevant Mold Infections
    Stuehler et al., The Journal of Infectious Disease (2015) - PMID: 25367298
  • Mycobacterium Tuberculosis-Specific and MHC Class I-Restricted CD8+ T-Cells Exhibit a Stem Cell Precursor-Like Phenotype in Patients with Active Pulmonary Tuberculosis
    Axelsson-Robertson et al., Int J Infect Dis. (2015) - PMID: 25809750
  • The Loss of BKV-Specific Immunity From Pretransplantation to Posttransplantation Identifies Kidney Transplant Recipients at Increased Risk of BKV Replication
    Schachtner et al., Am J Transplant. (2015) - PMID: 25808077
  • Diagnostics Reagents
    Jones et al., US Patent 20,150,093,766 (2015) - PMID: n.a.
  • CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells
    Wang et al., Clin Cancer Res. (2015) - PMID: 25838392
  • Selection of Adenovirus-specific and Epstein-Barr virus–specific T Cells With Major Histocompatibility Class I Streptamers Under Good Manufacturing Practice (GMP)–Compliant Conditions
    Freimüller et al., Cytotherapy (2015) - PMID: 25866178
  • Cutting Edge: Identification and Characterization of Human Intrahepatic CD49a+ NK Cells
    Marquardt et al., J Immunol. (2015) - PMID: 25672754
  • Potential role of CC Chemokine Receptor 6 (CCR6) in Prediction of Late‐onset CMV Infection Following Solid Organ Transplant
    Camargo et al., Clin Transplant. (2015) - PMID: 25690781
  • Polynucleotides for Treating Oncogenic Viral polypeptide Positive Tumors
    Lee et al., US Patent 20,150,023,996, (2015) - PMID: n.a.
  • Functional Exhaustion limits CD4+ and CD8+ T Cell Responses to Congenital Cytomegalovirus Infection
    Huygens et al., J Infect Dis. (2015) - PMID: 25657256
  • Early Exposure to Interleukin-21 Limits Rapidly Generated Anti–Epstein-Barr Virus T-cell Line Differentiation
    Orio et al., Cytotherapy. (2015) - PMID: 25661862
  • STAT3 Signaling Contributes to the High Effector Activities of Interleukin-15-derived Dendritic Cells
    Okada et al., Immunol Cell Biol. (2015) - PMID: 25582338
  • Human Papillomavirus 16-Specific T-Cell Responses and Spontaneous Regression of Anal High-Grade Squamous Intraepithelial Lesions
    Tong et al., J Infect Dis. (2015) - PMID: 25139018
  • Intracellular Cytokine Staining on PBMCs Using CyTOFTM Mass Cytometry
    Lin et al., - PMID: n.a.
  • The External Quality Assurance Oversight Laboratory (EQAPOL) Proficiency Program for IFN-gamma Enzyme-Linked ImmunoSpot (IFN-γ ELISpot) Assay
    Sanchez et al., J Immunol Methods. (2014) - PMID: n.a.
  • Establishment and Maintenance of a PBMC Repository for Functional Cellular Studies in Support of Clinical Vaccine Trials
    Sambor et al., J Immunol Methods. (2014) - PMID: 24787274
  • CMV Specific Cytokine Release Assay in Whole Blood is Optimized by Combining Synthetic CMV Peptides and Toll Like Receptor Agonists
    Dammermann et al., Journal of Immunological Methods (2014) - PMID: n.a.
  • Naïve and Memory CD8 T Cell Pool Homeostasis in Advanced Aging: Impact of Age and of Antigen-specificRresponses to Cytomegalovirus
    Vescovini et al., Age (Dordr). (2014) - PMID: 24318918
  • Preformed Frequencies of Cytomegalovirus (CMV)–Specific Memory T and B Cells Identify Protected CMV-Sensitized Individuals Among Seronegative Kidney Transplant Recipients
    Lúcia et al., Clinical Infectious Diseases (2014) - PMID: 25048845
  • A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein–Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer
    Taylor et al., Clin. Cancer Res. (2014) - PMID: 25124688
  • Human B Cells Produce Chemokine CXCL10 in the Presence of Mycobacterium Tuberculosis Specific T Cells
    Hoff et al., Tuberculosis (2014) - PMID: n.a.
  • Expression of the Human Cytomegalovirus UL11 Glycoprotein in Viral Infection and Evaluation of its Effect on Virus-Specific CD8 T Cells
    Gabaev et al., Journal of Virology (2014) - PMID: 25275132
  • HPV16-Specific T-Cell Responses and Spontaneous Regression of Anal High-Grade Squamous Intraepithelial Lesions
    Tong et al., J Infect Dis. (2014) - PMID: 25139018
  • Immune Responses Againgst Mycobacterium Tuberculosis Targets Associated to Latent and Active Tuberculosis Infection
    Montserrat Alvarez-Corrales, Published by Karolinska Institutet (2014) - PMID: n.a.
  • Preferential Infection of Human Ad5-Specific CD4 T Cells by HIV in Ad5 Naturally Exposed and Recombinant Ad5-HIV Vaccinated Individuals
    Hu et al., PNAS (2014) - PMID: 25197078
  • Diminished Humoral Responses Against and Reduced Gene Expression Levels of Human Endogenous Retrovirus-K (HERV-K) in Psoriasis
    Gupta et al., Journal of Translational Medicine (2014) - PMID: 25224121
  • Gene Therapy for Rhesus Monkeys Heterozygous for LDL Receptor Deficiency by Balloon Catheter Hepatic Delivery of Helper-Dependent Adenoviral Vector
    Oka et al., Gene Therapy (2014) - PMID: 25231173
  • Superior In Vitro Stimulation of Human CD8+ T-Cells by Whole Virus versus Split Virus Influenza Vaccines
    Halbroth et al., PLoS One (2014) - PMID: PLoS One (2014)
  • Activity of Broad-Spectrum T Cells as Treatment for AdV, EBV, CMV, BKV, and HHV6 Infections After HSCT
    Papadopoulou et al., Sci Transl Med. (2014) - PMID: 24964991
  • Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
    Fourati et al., JoVE (2014) - PMID: 25046399
  • The Role of CD4+ T Cells in BKV-Specific T Cell Immunity
    Weist et al., Med Microbiol Immunol. (2014) - PMID: 25052009
  • NetFCM: A Semi-Automated Web-Based Method for Flow Cytometry Data Analysis
    Frederiksen et al., Cytometry A. (2014) - PMID: 25044796
  • T-Bet and Eomes Are Differentially Linked to the Exhausted Phenotype of CD8+ T Cells in HIV Infection
    Buggert et al., PLoS Pathog. (2014) - PMID: 25032686
  • Specificities of Human CD4+ T Cell Responses to an Inactivated Flavivirus Vaccine and Infection: Correlation with Structure and Epitope Prediction
    Schwaiger et al., J Virol. (2014) - PMID: 24789782
  • Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19-IL2 Results in Sustained Clinical and Systemic Immunological Responses
    Weide et al., American Association for Cancer Research (2014) - PMID: n.a
  • BK Polyomavirus‐Specific Cellular Immune Responses Are Age‐Dependent and Strongly Correlate With Phases of Virus Replication
    Schmidt et al., American Journal of Transplantation (2014) - PMID: 24726000
  • MART-1 Peptide Vaccination Plus IMP321 (LAG-3Ig fusion protein) in Patients Receiving Autologous PBMCs After Lymphodepletion: Results of a Phase I Trial
    Romano et al., Journal of Translational Medicine (2014) - PMID: 24726012
  • TLR2-Dependent Protection Against Pneumococcal Carriage by Immunization with Lipidated Pneumococcal Proteins
    Moffitt et al., Infection and Immunol. (2014) - PMID: 24614661
  • An Enzyme-Linked Immunospot Assay for the Detection of Human Respiratory Syncytial Virus F-Specific IFNγ-producing T Cells
    Patton et al., Clin Vaccine Immunol. (2014) - PMID: 24574540
  • Influence of Frequent Infectious Exposures on General and Varicella-zoster Virus Specific Immune Responses in Pediatricians
    Ogunjimi et al., Clin Vaccine Immunol. (2014) - PMID: 24429070
  • Deficient EBV-Specific B- and T-Cell Response in Patients with Chronic Fatigue Syndrome
    Loebl et al., PLOS ONE (2014) - PMID: 24454857
  • HIV Infection in Uncircumcised Men Is Associated With Altered CD8 T-cell Function But Normal CD4 T-cell Numbers in the Foreskin
    Prodger et al., The Journal of Infectious Diseases (2014) - PMID: 24277744
  • Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins
    Bollard et al., J Clin Oncol. (2013) - PMID: 24344220
  • Cytomegalovirus Vaccine Strain Towne-Derived Dense Bodies Induce Broad Cellular Immune Responses and Neutralizing Antibodies that Prevent Infection of Fibroblasts and Epithelial Cells
    Cayatte et al., J. of Virology (2013) - PMID: 23926341
  • Mechanistic Insights Into the Impairment of Memory B Cells and Antibody Production in the Elderly
    Aberle et al., AGE (2013) - PMID: 22282053
  • Detection of Epstein-Barr Virus-Specific Memory CD4+ T Cells Using a Peptide-Based Cultured Enzyme-Linked Immunospot Assay
    Calarota et al., Immunology (2013) - PMID: 23560877
  • Nonreplicating Vaccines Can Protect African Green Monkeys from the Memphis 37 Strain of Respiratory Syncytial Virus
    Eyles et al., Journal of Infectious Diseases (2013) - PMID: 23596321
  • Overnight Resting of PBMC Changes Functional Signatures of Antigen Specific T- Cell Responses: Impact for Immune Monitoring within Clinical Trials
    Kutscher et al., PLoS One (2013) - PMID: 24146841
  • Inflammatory Activation and Recovering BKV-specific Immunity Correlate with Self-Limited BKV Replication after Renal Transplantation
    Schachtner et al., Transplant International (2013) - PMID: 24279642
  • Adoptive Immunotherapy with Antigen-Specific T Cells During Extracorporeal Membrane Oxygenation (ECMO) for Adenovirus-Related Respiratory Failure in a Child Given Haploidentical Stem Cell Transplantatio
    Di Nardo et al., Pediatric Blood & Cancer (2013) - PMID: 24039155
  • Rapid Generation of EBV-Specific Cytotoxic T Lymphocytes Resistant to Calcineurin Inhibitors for Adoptive Immunotherapy
    Ricciardelli et al., American Journal of Transplantation (2013) - PMID: 24266973
  • The Immunogenicity of Virus-Derived 2A Sequences in Immunocompetent Individuals
    Arber et al., Gene Therapy (2013) - PMID: 23698740
  • Adoptive T-Cell Transfer and Chemotherapy in the First-Line Treatment of Metastatic and/or Locally Recurrent Nasopharyngeal Carcinoma
    Chia et al., Molecular Therapy (2013) - PMID: 24297049
  • Combination of Epstein-Barr Virus Nuclear Antigen 1, 3 and Lytic Antigen BZLF1 Peptide Pools Allows Fast and Efficient Stimulation of Epstein-Barr Virus-Specific T Cells for Adoptive Immunotherapy
    Wang et al., Cytotherapy (2013) - PMID: 24094498
  • A Novel Cytomegalovirus-Induced Regulatory-Type T-Cell Subset Increases in Size During Older Life and Links Virus-Specific Immunity to Vascular Pathology
    Terrazzini et al., The Journal of Infectious Disease (2013) - PMID: 24203779
  • Putting Polyphosphates to the Test: Evidence Against Platelet-Induced Activation of Factor XII
    Faxälv et al., Blood (2013) - PMID: 23896408
  • Short-Term In-Vitro Expansion Improves Monitoring and Allows Affordable Generation of Virus-Specific T-Cells against Several Viruses for a Broad Clinical Application
    Geyeregger et al., PLOS ONE (2013) - PMID: 23630567
  • Adoptive Transfer of Epstein-Barr Virus (EBV) Nuclear Antigen 1–Specific T Cells As Treatment for EBV Reactivation and Lymphoproliferative Disorders After Allogeneic Stem-Cell Transplantation
    Icheva et al., JCO (2013) - PMID: 23169501
  • Human Papillomavirus Type 16 E6/E7-Specific Cytotoxic T Lymphocytes for Adoptive Immunotherapy of HPV-Associated Malignancies
    Ramos et al., Journal of Immunotherapy (2013) - PMID: 23211628
  • Cytomegalovirus-Specific CD4 and CD8 T Cell Responses in Infants and Children
    Lidehäll et al., Scandinavian Journal of Immunology (2013) - PMID: 23216075
  • The Effects of Age and Latent Cytomegalovirus Infection on the Redeployment of CD8+ T Cell Subsets in Response to Acute Exercise in Humans
    Spielmann et al., Brain, Behavior, and Immunity (2013) - PMID: 23684819
  • The Third Signal Cytokine IL-12 Rescues the Anti-Viral Function of Exhausted HBV-Specific CD8 T Cells
    Schurich et al., PLOS Pathogens (2013) - PMID: 23516358
  • Antibody Quality and Protection from Lethal Ebola Virus Challenge in Nonhuman Primates Immunized with Rabies Virus Based Bivalent Vaccine
    Blaney et al., PLOS Pathogens (2013) - PMID: 23737747
  • Donor-Derived CMV-Specific T Cells Reduce The Requirement For CMV-Directed Pharmacotherapy After Allogeneic Stem Cell Transplantation
    Blyth et al., Blood. (2013) - PMID: 23435462
  • Antigen-Reactive T Cell Enrichment for Direct, High-Resolution Analysis of the Human Naive and Memory Th Cell Repertoire
    Bacher et al., J. Immunol. (2013) - PMID: 23479226
  • An Adjuvanted Herpes Simplex Virus 2 Subunit Vaccine Elicits a T Cell Response in Mice and Is an Effective Therapeutic Vaccine in Guinea Pigs
    Skoberne et al., J. Virol. (2013) - PMID: 23365421
  • Distinct Gene-Expression Profiles Associated With the Susceptibility of Pathogen-Specific CD4 T Cells to HIV-1 Infection
    Hu et al., Blood. (2013) - PMID: 23258923
  • IL-7– and IL-15–Mediated TCR Sensitization Enables T Cell Responses to Self-Antigens
    Deshpande et al., J. Immunol. (2013) - PMID: 23325887
  • Up-Regulation of a Death Receptor Renders Antiviral T Cells Susceptible to NK Cell–Mediated Deletion
    Peppa et al., J. Exp. Med. (2012) - PMID: 23254287
  • Reconstitution of Protective Immune Responses against Cytomegalovirus and Varicella Zoster Virus Does Not Require Disease Development in Pediatric Recipients of Umbilical Cord Blood Transplantation
    Merindol et al., J. Immunol. (2012) - PMID: 23034171
  • Antiviral T Cell Response Triggers Cytomegalovirus Hepatitis in Mice
    Livingston-Rosanoff et al., J. Virol. (2012) - PMID: 22993151
  • Full-Length HIV-1 Immunogens Induce Greater Magnitude and Comparable Breadth of T Lymphocyte Responses to Conserved HIV-1 Regions Compared with Conserved-Region-Only HIV-1 Immunogens in Rhesus Monkeys
    Stephenson et al., J. Virol. (2012) - PMID: 22896617
  • Polyclonal Mucosa-Associated Invariant T Cells Have Unique Innate Functions in Bacterial Infection
    Chua et al., Infect. Immun. (2012) - PMID: 22778103
  • Differential Patterns of Large Tumor Antigen-Specific Immune Responsiveness in Patients with BK Polyomavirus-Positive Prostate Cancer or Benign Prostatic Hyperplasia
    Sais et al., J. Virol. (2012) - PMID: 22647697
  • Single-Cell Level Response of HIV-Specific and Cytomegalovirus-Specific CD4 T Cells Correlate With Viral Control in Chronic HIV-1 Subtype A Infection
    Eller et al., J Acquir Immune Defic Syndr (2012) - PMID: 22580564
  • A Novel Th Cell Epitope of Candida albicans Mediates Protection from Fungal Infection
    Bär et al., J. Immunol. (2012) - PMID: 22529294
  • Three Sensitive Assays Do Not Provide Evidence for Circulating HuD-specific T Cells in the Blood of Patients with Paraneoplastic Neurological Syndromes with Anti-Hu Antibodies
    de Jongste et al., Neuro Oncology. (2012) - PMID: 22591661
  • Performance of the QuantiFERON-Cytomegalovirus (CMV) Assay for Detection and Estimation of the Magnitude and Functionality of the CMV-Specific Gamma Interferon-Producing CD8+ T-Cell Response in Allogeneic Stem Cell Transplant Recipients
    Clari et al., Clin Vaccine Immunol May (2012) - PMID: 22379065
  • The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope
    de Souza et al., J. Immunol. (2012) - PMID: 22529301
  • Preferential Expansion of Human Virus-Specific Multifunctional Central Memory T Cells by Partial Targeting of the IL-2 Receptor Signaling Pathway: The Key Role of CD4+ T Cells
    Schmueck et al., J. Immunol. (2012) - PMID: 22516956
  • T-Cell Therapy for EBV-Associated Nasopharyngeal Carcinoma: Preparative Lymphodepleting Chemotherapy Does not Improve Clinical Results
    Secondino et al., Ann. Onc. (2012) - PMID: 21586688
  • A Whole Blood Monokine-Based Reporter Assay Provides a Sensitive and Robust Measurement of the Antigen-Specific T Cell Response
    Chakera et al., Journal of Translational Medicine (2011) - PMID: 21871084
  • Live and Inactivated Influenza Vaccines Induce Similar Humoral Responses, but Only Live Vaccines Induce Diverse T-Cell Responses in Young Children
    Hoft et al., The Journal of Infectious Disease (2011) - PMID: 21846636
  • Rebound of Residual Plasma Viremia After Initial Decrease Following Addition of Intravenous Immunoglobulin to Effective Antiretroviral Treatment of HIV
    Mellberg et al., AIDS Research and Therapy (2011) - PMID: 21708049
  • A Phase II Study Evaluating the Safety and Efficacy of an Adenovirus-LMP1-LMP2 Transduced Dendritic Cell Vaccine in Patients with Advanced Metastatic Nasopharyngeal Carcinoma
    Chia et al., Ann. Onc. (2011) - PMID: 21821548
  • Polyomavirus BK Large T-Antigen Derived Peptide Elicits a HLA-DR Promiscuous and Polyfunctional CD4+ T-cell Response
    Ramaswami et al., Clin. Vaccine Immunol (2011) - PMID: 21367979
  • Expansion of T Cells Targeting Multiple Antigens of Cytomegalovirus, Epstein – Barr Virus and Adenovirus to Provide Broad Antiviral Specificity After Stem Cell Transplantation
    Hanley et al., Cytotherapy (2011) - PMID: 21539497
  • Adoptive Transfer of EBV-Specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal Carcinoma
    Louis et al., J Immunother (2010) - PMID: 20948438
  • Effective and Long-Term Control of EBV PTLD After Transfer of Peptide-Selected T Cells
    Moosmann et al., Blood (2010) - PMID: 20103780
  • Accelerated Production of Antigen-Specific T-Cells for Pre-Clinical and Clinical Applications Using Gas-permeable Rapid Expansion Cultureware (G-Rex)
    Vera et al., J Immunother. (2010) - PMID: 20445351
  • Derivation of Human T Lymphocytes From Cord Blood and Peripheral Blood with Antiviral and Antileukemic Specificity from a Single Culture as Protection Against Infection and Relapse after Stem Cell Transplantation
    Micklethwaite et al., Blood (2010) - PMID: 20110422
  • Absence of Systemic Immune Response to Adenovectors After Intraocular Administration to Children With Retinoblastoma
    Ildefonso et al., Molecular Therapy (2010) - PMID: 20606647
  • Nucleofection of DCs to Generate Multivirusspecific T Cells for Prevention or Treatment of Viral Infections in the Immunocompromised Host
    Gerdemann et al., Molecular Therapy (2009) - PMID: 19584818
  • Cytotoxic T Lymphocyte Therapy with Donor T Cells Prevents and Treats Adenovirus and Epstein-Barr Virus Infections after Haploidentical and Matched Unrelated Stem Cell Transplantation
    Leen et al., Blood (2009) - PMID: 19700662
  • Tuberculosis Subunit Vaccination Provides Long-Term Protective Immunity Characterized by Multifunctional CD4 Memory T Cells
    Lindenstrom et al., J. Immunol (2009) - PMID: 19494330
  • Enhancing the In Vivo Expansion of Adoptively Transferred EBV-Specific CTL with Lymphodepleting CD45 Monoclonal Antibodies in NPC Patients
    Louis et al., Blood (2009) - PMID: 18971421
  • Mesenchymal Stem Cells Exert Differential Effects on Alloantigen and Virus-Specific T-cell Responses
    Karlsson et al., Blood (2008) - PMID: 18445691
  • Prospective Monitoring of Polyomavirus BK Replication and Impact of Pre-Emptive Intervention in Pediatric Kidney Recipients
    Ginevri et al., American Journal of Transplantation (2007) - PMID: 17908275
  • Contact-Activated Monocytes: Efficient Antigen Presenting Cells for the Stimulation of Antigen-specific T cells
    Leen et al., J Immunother (2007) - PMID: 17198088

Check our list of products, click and go.

Get a quote